<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39408818</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>16</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>19</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1422-0067</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>19</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>29</Day></PubDate></JournalIssue><Title>International journal of molecular sciences</Title><ISOAbbreviation>Int J Mol Sci</ISOAbbreviation></Journal><ArticleTitle>Cholesterol and Cholesterol-Lowering Medications in COVID-19-An Unresolved Matter.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">10489</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms251910489</ELocationID><Abstract><AbstractText>Infections with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) cause coronavirus disease 2019 (COVID-19), a disease with very heterogeneous symptoms. Dyslipidaemia is prevalent in at least 20% of Europeans, and dyslipidaemia before SARS-CoV-2 infection increases the risk for severe COVID-19 and mortality by 139%. Many reports described reduced serum cholesterol levels in virus-infected patients, in particular in those with severe disease. The liver is the major organ for lipid homeostasis and hepatic dysfunction appears to occur in one in five patients infected with SARS-CoV-2. Thus, SARS-CoV-2 infection, COVID-19 disease severity and liver injury may be related to impaired cholesterol homeostasis. These observations prompted efforts to assess the therapeutic opportunities of cholesterol-lowering medications to reduce COVID-19 severity. The majority of studies implicate statins to have beneficial effects on disease severity and outcome in COVID-19. Proprotein convertase subtilisin/kexin type 9 (PCSK9) antibodies have also shown potential to protect against COVID-19. This review describes the relationship between systemic cholesterol levels, liver injury and COVID-19 disease severity. The potential effects of statins and PCSK9 in COVID-19 are summarised. Finally, the relationship between cholesterol and lung function, the first organ to be affected by SARS-CoV-2, is described.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Grewal</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-7937-8887</Identifier><AffiliationInfo><Affiliation>School of Pharmacy, Faculty of Medicine and Health, University of Sydney, Sydney, NSW 2006, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nguyen</LastName><ForeName>Mai Khanh Linh</ForeName><Initials>MKL</Initials><AffiliationInfo><Affiliation>School of Pharmacy, Faculty of Medicine and Health, University of Sydney, Sydney, NSW 2006, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Buechler</LastName><ForeName>Christa</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-5635-3994</Identifier><AffiliationInfo><Affiliation>Department of Internal Medicine I, Regensburg University Hospital, 93053 Regensburg, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Int J Mol Sci</MedlineTA><NlmUniqueID>101092791</NlmUniqueID><ISSNLinking>1422-0067</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>97C5T2UQ7J</RegistryNumber><NameOfSubstance UI="D002784">Cholesterol</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019161">Hydroxymethylglutaryl-CoA Reductase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000924">Anticholesteremic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.21.-</RegistryNumber><NameOfSubstance UI="C472125">PCSK9 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.21.-</RegistryNumber><NameOfSubstance UI="D000071449">Proprotein Convertase 9</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002784" MajorTopicYN="Y">Cholesterol</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000093485" MajorTopicYN="Y">COVID-19 Drug Treatment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019161" MajorTopicYN="Y">Hydroxymethylglutaryl-CoA Reductase Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000924" MajorTopicYN="N">Anticholesteremic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D050171" MajorTopicYN="N">Dyslipidemias</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000071449" MajorTopicYN="N">Proprotein Convertase 9</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008099" MajorTopicYN="N">Liver</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">LDL receptor</Keyword><Keyword MajorTopicYN="N">albumin</Keyword><Keyword MajorTopicYN="N">aminotransferase</Keyword><Keyword MajorTopicYN="N">statin</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>9</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>16</Day><Hour>10</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>16</Day><Hour>10</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>16</Day><Hour>1</Hour><Minute>8</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>29</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39408818</ArticleId><ArticleId IdType="pmc">PMC11477656</ArticleId><ArticleId IdType="doi">10.3390/ijms251910489</ArticleId><ArticleId IdType="pii">ijms251910489</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Shappell C.N., Klompas M., Chan C., Chen T., Kanjilal S., McKenna C., Rhee C., CDC Prevention Epicenters Program Use of Electronic Clinical Data to Track Incidence and Mortality for SARS-CoV-2-Associated Sepsis. JAMA Netw. Open. 2023;6:e2335728. doi: 10.1001/jamanetworkopen.2023.35728.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2023.35728</ArticleId><ArticleId IdType="pmc">PMC10543118</ArticleId><ArticleId IdType="pubmed">37773495</ArticleId></ArticleIdList></Reference><Reference><Citation>Cesar-Silva D., Pereira-Dutra F.S., Moraes Giannini A.L., Jacques G.d.A.C. The Endolysosomal System: The Acid Test for SARS-CoV-2. Int. J. Mol. Sci. 2022;23:4576. doi: 10.3390/ijms23094576.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms23094576</ArticleId><ArticleId IdType="pmc">PMC9105036</ArticleId><ArticleId IdType="pubmed">35562967</ArticleId></ArticleIdList></Reference><Reference><Citation>Grewal T., Nguyen M.K.L., Buechler C. Cholesterol and COVID-19-therapeutic opportunities at the host/virus interface during cell entry. Life Sci. Alliance. 2024;7:e202302453. doi: 10.26508/lsa.202302453.</Citation><ArticleIdList><ArticleId IdType="doi">10.26508/lsa.202302453</ArticleId><ArticleId IdType="pmc">PMC10883773</ArticleId><ArticleId IdType="pubmed">38388172</ArticleId></ArticleIdList></Reference><Reference><Citation>Uppal S., Postnikova O., Villasmil R., Rogozin I.B., Bocharov A.V., Eggerman T.L., Poliakov E., Redmond T.M. Low-Density Lipoprotein Receptor (LDLR) Is Involved in Internalization of Lentiviral Particles Pseudotyped with SARS-CoV-2 Spike Protein in Ocular Cells. Int. J. Mol. Sci. 2023;24:11860. doi: 10.3390/ijms241411860.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms241411860</ArticleId><ArticleId IdType="pmc">PMC10380832</ArticleId><ArticleId IdType="pubmed">37511618</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakurai Y., Okada S., Ozeki T., Yoshikawa R., Kinoshita T., Yasuda J. SARS-CoV-2 Omicron subvariants progressively adapt to human cells with altered host cell entry. mSphere. 2024;9:e0033824. doi: 10.1128/msphere.00338-24.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/msphere.00338-24</ArticleId><ArticleId IdType="pmc">PMC11423564</ArticleId><ArticleId IdType="pubmed">39191389</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson C.B., Farzan M., Chen B., Choe H. Mechanisms of SARS-CoV-2 entry into cells. Nat. Rev. Mol. Cell Biol. 2022;23:3–20. doi: 10.1038/s41580-021-00418-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41580-021-00418-x</ArticleId><ArticleId IdType="pmc">PMC8491763</ArticleId><ArticleId IdType="pubmed">34611326</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X., Yuan H., Li X., Wang H. Spike protein mediated membrane fusion during SARS-CoV-2 infection. J. Med. Virol. 2023;95:e282122023. doi: 10.1002/jmv.28212.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.28212</ArticleId><ArticleId IdType="pmc">PMC9874878</ArticleId><ArticleId IdType="pubmed">36224449</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim S., Zhang M., Chang T.L. ACE2-Independent Alternative Receptors for SARS-CoV-2. Viruses. 2022;14:2535. doi: 10.3390/v14112535.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v14112535</ArticleId><ArticleId IdType="pmc">PMC9692829</ArticleId><ArticleId IdType="pubmed">36423144</ArticleId></ArticleIdList></Reference><Reference><Citation>Hilser J.R., Han Y., Biswas S., Gukasyan J., Cai Z., Zhu R., Tang W.H.W., Deb A., Lusis A.J., Hartiala J.A., et al. Association of serum HDL-cholesterol and apolipoprotein A1 levels with risk of severe SARS-CoV-2 infection. J. Lipid Res. 2021;62:100061. doi: 10.1016/j.jlr.2021.100061.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jlr.2021.100061</ArticleId><ArticleId IdType="pmc">PMC7923911</ArticleId><ArticleId IdType="pubmed">33667465</ArticleId></ArticleIdList></Reference><Reference><Citation>Scalsky R.J., Chen Y.J., Desai K., O’Connell J.R., Perry J.A., Hong C.C. Baseline cardiometabolic profiles and SARS-CoV-2 infection in the UK Biobank. PLoS ONE. 2021;16:e0248602. doi: 10.1371/journal.pone.0248602.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0248602</ArticleId><ArticleId IdType="pmc">PMC8016301</ArticleId><ArticleId IdType="pubmed">33793566</ArticleId></ArticleIdList></Reference><Reference><Citation>Al Youha S., Alowaish O., Ibrahim I.K., Alghounaim M., Abu-Sheasha G.A., Fakhra Z., Al Hendi S., AlQabandi Y., Almazeedi S., Al Asoomi F., et al. Factors associated with SARS-CoV-2 infection amongst healthcare workers in a COVID-19 designated hospital. J. Infect. Public Health. 2021;14:1226–1232. doi: 10.1016/j.jiph.2021.08.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jiph.2021.08.012</ArticleId><ArticleId IdType="pmc">PMC8366051</ArticleId><ArticleId IdType="pubmed">34450510</ArticleId></ArticleIdList></Reference><Reference><Citation>Hariyanto T.I., Kurniawan A. Dyslipidemia is associated with severe coronavirus disease 2019 (COVID-19) infection. Diabetes Metab. Syndr. 2020;14:1463–1465. doi: 10.1016/j.dsx.2020.07.054.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dsx.2020.07.054</ArticleId><ArticleId IdType="pmc">PMC7395301</ArticleId><ArticleId IdType="pubmed">32771919</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin H., He J., Dong C., Li B., Ma Z., Li B., Huang T., Fan J., He G., Zhao X. Altered Lipid Profile Is a Risk Factor for the Poor Progression of COVID-19: From Two Retrospective Cohorts. Front. Cell Infect. Microbiol. 2021;11:712530. doi: 10.3389/fcimb.2021.712530.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcimb.2021.712530</ArticleId><ArticleId IdType="pmc">PMC8515140</ArticleId><ArticleId IdType="pubmed">34660338</ArticleId></ArticleIdList></Reference><Reference><Citation>Barman H.A., Pala A.S., Dogan O., Atici A., Yumuk M.T., Alici G., Sit O., Gungor B., Dogan S.M. Prognostic significance of temporal changes of lipid profile in COVID-19 patients. Obes. Med. 2021;28:100373. doi: 10.1016/j.obmed.2021.100373.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.obmed.2021.100373</ArticleId><ArticleId IdType="pmc">PMC8516440</ArticleId><ArticleId IdType="pubmed">34671707</ArticleId></ArticleIdList></Reference><Reference><Citation>Feingold K.R. The bidirectional interaction of COVID-19 infections and lipoproteins. Best Pract. Res. Clin. Endocrinol. Metab. 2023;37:101751. doi: 10.1016/j.beem.2023.101751.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.beem.2023.101751</ArticleId><ArticleId IdType="pmc">PMC9951034</ArticleId><ArticleId IdType="pubmed">36894344</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang G., Deng J., Li J., Wu C., Dong H., Wu S., Zhong Y. The Role of High-Density Lipoprotein in COVID-19. Front. Pharmacol. 2021;12:720283. doi: 10.3389/fphar.2021.720283.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2021.720283</ArticleId><ArticleId IdType="pmc">PMC8322438</ArticleId><ArticleId IdType="pubmed">34335279</ArticleId></ArticleIdList></Reference><Reference><Citation>Chidambaram V., Shanmugavel Geetha H., Kumar A., Majella M.G., Sivakumar R.K., Voruganti D., Mehta J.L., Karakousis P.C. Association of Lipid Levels With COVID-19 Infection, Disease Severity and Mortality: A Systematic Review and Meta-Analysis. Front. Cardiovasc. Med. 2022;9:862999. doi: 10.3389/fcvm.2022.862999.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcvm.2022.862999</ArticleId><ArticleId IdType="pmc">PMC8988060</ArticleId><ArticleId IdType="pubmed">35402531</ArticleId></ArticleIdList></Reference><Reference><Citation>Kukla M., Menzyk T., Dembinski M., Winiarski M., Garlicki A., Bociaga-Jasik M., Skonieczna M., Hudy D., Maziarz B., Kusnierz-Cabala B., et al. Anti-inflammatory adipokines: Chemerin, vaspin, omentin concentrations and SARS-CoV-2 outcomes. Sci. Rep. 2021;11:21514. doi: 10.1038/s41598-021-00928-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-00928-w</ArticleId><ArticleId IdType="pmc">PMC8563971</ArticleId><ArticleId IdType="pubmed">34728695</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruscica M., Macchi C., Iodice S., Tersalvi G., Rota I., Ghidini S., Terranova L., Valenti L., Amati F., Aliberti S., et al. Prognostic parameters of in-hospital mortality in COVID-19 patients-An Italian experience. Eur. J. Clin. Invest. 2021;51:e13629. doi: 10.1111/eci.13629.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/eci.13629</ArticleId><ArticleId IdType="pmc">PMC8420178</ArticleId><ArticleId IdType="pubmed">34184268</ArticleId></ArticleIdList></Reference><Reference><Citation>Sampedro-Nunez M., Aguirre-Moreno N., Garcia-Fraile Fraile L., Jimenez-Blanco S., Knott-Torcal C., Sanz-Martin P., Fernandez-Jimenez G., Marazuela M. Finding answers in lipid profile in COVID-19 patients. Endocrine. 2021;74:443–454. doi: 10.1007/s12020-021-02881-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12020-021-02881-0</ArticleId><ArticleId IdType="pmc">PMC8525620</ArticleId><ArticleId IdType="pubmed">34668172</ArticleId></ArticleIdList></Reference><Reference><Citation>Bianconi V., Mannarino M.R., Cosentini E., Figorilli F., Colangelo C., Cellini G., Braca M., Lombardini R., Paltriccia R., Sahebkar A., et al. The impact of statin therapy on in-hospital prognosis and endothelial function of patients at high-to-very high cardiovascular risk admitted for COVID-19. J. Med. Virol. 2023;95:e28678. doi: 10.1002/jmv.28678.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.28678</ArticleId><ArticleId IdType="pubmed">36929742</ArticleId></ArticleIdList></Reference><Reference><Citation>Chow R., Im J., Chiu N., Chiu L., Aggarwal R., Lee J., Choi Y.G., Prsic E.H., Shin H.J. The protective association between statins use and adverse outcomes among COVID-19 patients: A systematic review and meta-analysis. PLoS ONE. 2021;16:e0253576. doi: 10.1371/journal.pone.0253576.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0253576</ArticleId><ArticleId IdType="pmc">PMC8224908</ArticleId><ArticleId IdType="pubmed">34166458</ArticleId></ArticleIdList></Reference><Reference><Citation>Lao U.S., Law C.F., Baptista-Hon D.T., Tomlinson B. Systematic Review and Meta-Analysis of Statin Use and Mortality, Intensive Care Unit Admission and Requirement for Mechanical Ventilation in COVID-19 Patients. J. Clin. Med. 2022;11:5454. doi: 10.3390/jcm11185454.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm11185454</ArticleId><ArticleId IdType="pmc">PMC9501062</ArticleId><ArticleId IdType="pubmed">36143101</ArticleId></ArticleIdList></Reference><Reference><Citation>Hariyanto T.I., Kurniawan A. Statin therapy did not improve the in-hospital outcome of coronavirus disease 2019 (COVID-19) infection. Diabetes Metab. Syndr. 2020;14:1613–1615. doi: 10.1016/j.dsx.2020.08.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dsx.2020.08.023</ArticleId><ArticleId IdType="pmc">PMC7448951</ArticleId><ArticleId IdType="pubmed">32882643</ArticleId></ArticleIdList></Reference><Reference><Citation>Barrantes F.J. The constellation of cholesterol-dependent processes associated with SARS-CoV-2 infection. Prog. Lipid Res. 2022;87:101166. doi: 10.1016/j.plipres.2022.101166.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.plipres.2022.101166</ArticleId><ArticleId IdType="pmc">PMC9059347</ArticleId><ArticleId IdType="pubmed">35513161</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao S., Ren J., Xu Y., Lin J., Pan C., Meng Y., Xu N. Studies in the antiviral molecular mechanisms of 25-hydroxycholesterol: Disturbing cholesterol homeostasis and post-translational modification of proteins. Eur. J. Pharmacol. 2022;926:175033. doi: 10.1016/j.ejphar.2022.175033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejphar.2022.175033</ArticleId><ArticleId IdType="pmc">PMC9119167</ArticleId><ArticleId IdType="pubmed">35598845</ArticleId></ArticleIdList></Reference><Reference><Citation>Palacios-Rapalo S.N., De Jesús-González L.A., Cordero-Rivera C.D., Farfan-Morales C.N., Osuna-Ramos J.F., Martinez-Mier G., Quistián-Galván J., Muñoz-Pérez A., Bernal-Dolores V., del Angel R.M., et al. Cholesterol-Rich Lipid Rafts as Platforms for SARS-CoV-2 Entry. Front. Immunol. 2021;12:796855. doi: 10.3389/fimmu.2021.796855.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.796855</ArticleId><ArticleId IdType="pmc">PMC8719300</ArticleId><ArticleId IdType="pubmed">34975904</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang Y., Hu L., Liu Y., Zhou B., Qin X., Ye J., Shen M., Wu Z., Zhang P. Possible mechanisms of cholesterol elevation aggravating COVID-19. Int. J. Med. Sci. 2021;18:3533–3543. doi: 10.7150/ijms.62021.</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/ijms.62021</ArticleId><ArticleId IdType="pmc">PMC8436106</ArticleId><ArticleId IdType="pubmed">34522180</ArticleId></ArticleIdList></Reference><Reference><Citation>Makhoul E., Aklinski J.L., Miller J., Leonard C., Backer S., Kahar P., Parmar M.S., Khanna D. A Review of COVID-19 in Relation to Metabolic Syndrome: Obesity, Hypertension, Diabetes, and Dyslipidemia. Cureus. 2022;14:e27438. doi: 10.7759/cureus.27438.</Citation><ArticleIdList><ArticleId IdType="doi">10.7759/cureus.27438</ArticleId><ArticleId IdType="pmc">PMC9420458</ArticleId><ArticleId IdType="pubmed">36051728</ArticleId></ArticleIdList></Reference><Reference><Citation>Abou-Hamdan M., Saleh R., Mani S., Dournaud P., Metifiot M., Blondot M.L., Andreola M.L., Abdel-Sater F., De Reggi M., Gressens P., et al. Potential antiviral effects of pantethine against SARS-CoV-2. Sci. Rep. 2023;13:2237. doi: 10.1038/s41598-023-29245-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-023-29245-0</ArticleId><ArticleId IdType="pmc">PMC9906591</ArticleId><ArticleId IdType="pubmed">36754974</ArticleId></ArticleIdList></Reference><Reference><Citation>Enrich C., Rentero C., Hierro A., Grewal T. Role of cholesterol in SNARE-mediated trafficking on intracellular membranes. J. Cell Sci. 2015;128:1071–1081. doi: 10.1242/jcs.164459.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/jcs.164459</ArticleId><ArticleId IdType="pubmed">25653390</ArticleId></ArticleIdList></Reference><Reference><Citation>Mesmin B., Maxfield F.R. Intracellular sterol dynamics. Biochim. Biophys. Acta. 2009;1791:636–645. doi: 10.1016/j.bbalip.2009.03.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbalip.2009.03.002</ArticleId><ArticleId IdType="pmc">PMC2696574</ArticleId><ArticleId IdType="pubmed">19286471</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H., Yuan Z., Pavel M.A., Jablonski S.M., Jablonski J., Hobson R., Valente S., Reddy C.B., Hansen S.B. The role of high cholesterol in SARS-CoV-2 infectivity. J. Biol. Chem. 2023;299:104763. doi: 10.1016/j.jbc.2023.104763.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbc.2023.104763</ArticleId><ArticleId IdType="pmc">PMC10140059</ArticleId><ArticleId IdType="pubmed">37119851</ArticleId></ArticleIdList></Reference><Reference><Citation>Wing P.A.C., Schmidt N.M., Peters R., Erdmann M., Brown R., Wang H., Swadling L., Investigators C.O., Newman J., Thakur N., et al. An ACAT inhibitor suppresses SARS-CoV-2 replication and boosts antiviral T cell activity. PLoS Pathog. 2023;19:e1011323. doi: 10.1371/journal.ppat.1011323.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1011323</ArticleId><ArticleId IdType="pmc">PMC10202285</ArticleId><ArticleId IdType="pubmed">37134108</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan Z., Pavel M.A., Wang H., Kwachukwu J.C., Mediouni S., Jablonski J.A., Nettles K.W., Reddy C.B., Valente S.T., Hansen S.B. Hydroxychloroquine blocks SARS-CoV-2 entry into the endocytic pathway in mammalian cell culture. Commun. Biol. 2022;5:958. doi: 10.1038/s42003-022-03841-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s42003-022-03841-8</ArticleId><ArticleId IdType="pmc">PMC9472185</ArticleId><ArticleId IdType="pubmed">36104427</ArticleId></ArticleIdList></Reference><Reference><Citation>Kovacs T., Kurtan K., Varga Z., Nagy P., Panyi G., Zakany F. Veklury(R) (remdesivir) formulations inhibit initial membrane-coupled events of SARS-CoV-2 infection due to their sulfobutylether-beta-cyclodextrin content. Br. J. Pharmacol. 2023;180:2064–2084. doi: 10.1111/bph.16063.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bph.16063</ArticleId><ArticleId IdType="pubmed">36848880</ArticleId></ArticleIdList></Reference><Reference><Citation>Li G.M., Li Y.G., Yamate M., Li S.M., Ikuta K. Lipid rafts play an important role in the early stage of severe acute respiratory syndrome-coronavirus life cycle. Microbes Infect. 2007;9:96–102. doi: 10.1016/j.micinf.2006.10.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.micinf.2006.10.015</ArticleId><ArticleId IdType="pmc">PMC7110773</ArticleId><ArticleId IdType="pubmed">17194611</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu Y., Liu D.X., Tam J.P. Lipid rafts are involved in SARS-CoV entry into Vero E6 cells. Biochem. Biophys. Res. Commun. 2008;369:344–349. doi: 10.1016/j.bbrc.2008.02.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2008.02.023</ArticleId><ArticleId IdType="pmc">PMC7092920</ArticleId><ArticleId IdType="pubmed">18279660</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S., Li W., Hui H., Tiwari S.K., Zhang Q., Croker B.A., Rawlings S., Smith D., Carlin A.F., Rana T.M. Cholesterol 25-Hydroxylase inhibits SARS-CoV-2 and other coronaviruses by depleting membrane cholesterol. EMBO J. 2020;39:e106057. doi: 10.15252/embj.2020106057.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embj.2020106057</ArticleId><ArticleId IdType="pmc">PMC7537045</ArticleId><ArticleId IdType="pubmed">32944968</ArticleId></ArticleIdList></Reference><Reference><Citation>Murae M., Sakai S., Miyata N., Shimizu Y., Okemoto-Nakamura Y., Kishimoto T., Ogawa M., Tani H., Tanaka K., Noguchi K., et al. Inhibition Mechanism of SARS-CoV-2 Infection by a Cholesterol Derivative, Nat-20(S)-yne. Biol. Pharm. Bull. 2024;47:930–940. doi: 10.1248/bpb.b23-00797.</Citation><ArticleIdList><ArticleId IdType="doi">10.1248/bpb.b23-00797</ArticleId><ArticleId IdType="pubmed">38692871</ArticleId></ArticleIdList></Reference><Reference><Citation>Kulma M., Sakanovic A., Bedina-Zavec A., Caserman S., Omersa N., Solinc G., Orehek S., Hafner-Bratkovic I., Kuhar U., Slavec B., et al. Sequestration of membrane cholesterol by cholesterol-binding proteins inhibits SARS-CoV-2 entry into Vero E6 cells. Biochem. Biophys. Res. Commun. 2024;716:149954. doi: 10.1016/j.bbrc.2024.149954.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2024.149954</ArticleId><ArticleId IdType="pubmed">38704887</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu J., Chen L., Qin C., Huo F., Liang X., Yang X., Zhang K., Lin P., Liu J., Feng Z., et al. CD147 contributes to SARS-CoV-2-induced pulmonary fibrosis. Signal Transduct. Target. Ther. 2022;7:382. doi: 10.1038/s41392-022-01230-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-022-01230-5</ArticleId><ArticleId IdType="pmc">PMC9691700</ArticleId><ArticleId IdType="pubmed">36424379</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanyenda L.J., Verdile G., Martins R., Meloni B.P., Chieng J., Mastaglia F., Laws S.M., Anderton R.S., Boulos S. Is cholesterol and amyloid-beta stress induced CD147 expression a protective response? Evidence that extracellular cyclophilin a mediated neuroprotection is reliant on CD147. J. Alzheimers Dis. 2014;39:545–556. doi: 10.3233/JAD-131442.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-131442</ArticleId><ArticleId IdType="pubmed">24217276</ArticleId></ArticleIdList></Reference><Reference><Citation>Bestle D., Heindl M.R., Limburg H., Van Lam van T., Pilgram O., Moulton H., Stein D.A., Hardes K., Eickmann M., Dolnik O., et al. TMPRSS2 and furin are both essential for proteolytic activation of SARS-CoV-2 in human airway cells. Life Sci. Alliance. 2020;3:e202000786. doi: 10.26508/lsa.202000786.</Citation><ArticleIdList><ArticleId IdType="doi">10.26508/lsa.202000786</ArticleId><ArticleId IdType="pmc">PMC7383062</ArticleId><ArticleId IdType="pubmed">32703818</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang T., Jaimes J.A., Bidon M.K., Straus M.R., Daniel S., Whittaker G.R. Proteolytic Activation of SARS-CoV-2 Spike at the S1/S2 Boundary: Potential Role of Proteases beyond Furin. ACS Infect. Dis. 2021;7:264–272. doi: 10.1021/acsinfecdis.0c00701.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsinfecdis.0c00701</ArticleId><ArticleId IdType="pmc">PMC7839419</ArticleId><ArticleId IdType="pubmed">33432808</ArticleId></ArticleIdList></Reference><Reference><Citation>Ripa I., Andreu S., Lopez-Guerrero J.A., Bello-Morales R. Membrane Rafts: Portals for Viral Entry. Front. Microbiol. 2021;12:631274. doi: 10.3389/fmicb.2021.631274.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2021.631274</ArticleId><ArticleId IdType="pmc">PMC7890030</ArticleId><ArticleId IdType="pubmed">33613502</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanders D.W., Jumper C.C., Ackerman P.J., Bracha D., Donlic A., Kim H., Kenney D., Castello-Serrano I., Suzuki S., Tamura T., et al. SARS-CoV-2 requires cholesterol for viral entry and pathological syncytia formation. eLife. 2021;10:e65962. doi: 10.7554/eLife.65962.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.65962</ArticleId><ArticleId IdType="pmc">PMC8104966</ArticleId><ArticleId IdType="pubmed">33890572</ArticleId></ArticleIdList></Reference><Reference><Citation>Meher G., Bhattacharjya S., Chakraborty H. Membrane cholesterol regulates the oligomerization and fusogenicity of SARS-CoV fusion peptide: Implications in viral entry. Phys. Chem. Chem. Phys. 2023;25:7815–7824. doi: 10.1039/D2CP04741A.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/D2CP04741A</ArticleId><ArticleId IdType="pubmed">36857640</ArticleId></ArticleIdList></Reference><Reference><Citation>Essalmani R., Andreo U., Evagelidis A., Le Devehat M., Pereira Ramos O.H., Fruchart Gaillard C., Susan-Resiga D., Cohen E.A., Seidah N.G. SKI-1/S1P Facilitates SARS-CoV-2 Spike Induced Cell-to-Cell Fusion via Activation of SREBP-2 and Metalloproteases, Whereas PCSK9 Enhances the Degradation of ACE2. Viruses. 2023;15:360. doi: 10.3390/v15020360.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v15020360</ArticleId><ArticleId IdType="pmc">PMC9959508</ArticleId><ArticleId IdType="pubmed">36851576</ArticleId></ArticleIdList></Reference><Reference><Citation>Ou X., Liu Y., Lei X., Li P., Mi D., Ren L., Guo L., Guo R., Chen T., Hu J., et al. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nat. Commun. 2020;11:1620. doi: 10.1038/s41467-020-15562-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-15562-9</ArticleId><ArticleId IdType="pmc">PMC7100515</ArticleId><ArticleId IdType="pubmed">32221306</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang T., Bidon M., Jaimes J.A., Whittaker G.R., Daniel S. Coronavirus membrane fusion mechanism offers a potential target for antiviral development. Antivir. Res. 2020;178:104792. doi: 10.1016/j.antiviral.2020.104792.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2020.104792</ArticleId><ArticleId IdType="pmc">PMC7194977</ArticleId><ArticleId IdType="pubmed">32272173</ArticleId></ArticleIdList></Reference><Reference><Citation>Carette J.E., Raaben M., Wong A.C., Herbert A.S., Obernosterer G., Mulherkar N., Kuehne A.I., Kranzusch P.J., Griffin A.M., Ruthel G., et al. Ebola virus entry requires the cholesterol transporter Niemann-Pick C1. Nature. 2011;477:340–343. doi: 10.1038/nature10348.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature10348</ArticleId><ArticleId IdType="pmc">PMC3175325</ArticleId><ArticleId IdType="pubmed">21866103</ArticleId></ArticleIdList></Reference><Reference><Citation>Cote M., Misasi J., Ren T., Bruchez A., Lee K., Filone C.M., Hensley L., Li Q., Ory D., Chandran K., et al. Small molecule inhibitors reveal Niemann-Pick C1 is essential for Ebola virus infection. Nature. 2011;477:344–348. doi: 10.1038/nature10380.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature10380</ArticleId><ArticleId IdType="pmc">PMC3230319</ArticleId><ArticleId IdType="pubmed">21866101</ArticleId></ArticleIdList></Reference><Reference><Citation>Schloer S., Goretzko J., Pleschka S., Ludwig S., Rescher U. Combinatory Treatment with Oseltamivir and Itraconazole Targeting Both Virus and Host Factors in Influenza A Virus Infection. Viruses. 2020;12:703. doi: 10.3390/v12070703.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v12070703</ArticleId><ArticleId IdType="pmc">PMC7412427</ArticleId><ArticleId IdType="pubmed">32610711</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuhnl A., Musiol A., Heitzig N., Johnson D.E., Ehrhardt C., Grewal T., Gerke V., Ludwig S., Rescher U. Late Endosomal/Lysosomal Cholesterol Accumulation Is a Host Cell-Protective Mechanism Inhibiting Endosomal Escape of Influenza A Virus. mBio. 2018;9:01345-18. doi: 10.1128/mBio.01345-18.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mBio.01345-18</ArticleId><ArticleId IdType="pmc">PMC6058292</ArticleId><ArticleId IdType="pubmed">30042202</ArticleId></ArticleIdList></Reference><Reference><Citation>Musiol A., Gran S., Ehrhardt C., Ludwig S., Grewal T., Gerke V., Rescher U. Annexin A6-balanced late endosomal cholesterol controls influenza A replication and propagation. mBio. 2013;4:e00608-13. doi: 10.1128/mBio.00608-13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mBio.00608-13</ArticleId><ArticleId IdType="pmc">PMC3892785</ArticleId><ArticleId IdType="pubmed">24194536</ArticleId></ArticleIdList></Reference><Reference><Citation>Schloer S., Goretzko J., Kuhnl A., Brunotte L., Ludwig S., Rescher U. The clinically licensed antifungal drug itraconazole inhibits influenza virus in vitro and in vivo. Emerg. Microbes Infect. 2019;8:80–93. doi: 10.1080/22221751.2018.1559709.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2018.1559709</ArticleId><ArticleId IdType="pmc">PMC6455256</ArticleId><ArticleId IdType="pubmed">30866762</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang I.C., Bosch B.J., Li F., Li W., Lee K.H., Ghiran S., Vasilieva N., Dermody T.S., Harrison S.C., Dormitzer P.R., et al. SARS coronavirus, but not human coronavirus NL63, utilizes cathepsin L to infect ACE2-expressing cells. J. Biol. Chem. 2006;281:3198–3203. doi: 10.1074/jbc.M508381200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M508381200</ArticleId><ArticleId IdType="pmc">PMC8010168</ArticleId><ArticleId IdType="pubmed">16339146</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou N., Pan T., Zhang J., Li Q., Zhang X., Bai C., Huang F., Peng T., Zhang J., Liu C., et al. Glycopeptide Antibiotics Potently Inhibit Cathepsin L in the Late Endosome/Lysosome and Block the Entry of Ebola Virus, Middle East Respiratory Syndrome Coronavirus (MERS-CoV), and Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) J. Biol. Chem. 2016;291:9218–9232. doi: 10.1074/jbc.M116.716100.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M116.716100</ArticleId><ArticleId IdType="pmc">PMC4861487</ArticleId><ArticleId IdType="pubmed">26953343</ArticleId></ArticleIdList></Reference><Reference><Citation>Datta G., Rezagholizadeh N., Hasler W.A., Khan N., Chen X. SLC38A9 regulates SARS-CoV-2 viral entry. iScience. 2024;27:110387. doi: 10.1016/j.isci.2024.110387.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.isci.2024.110387</ArticleId><ArticleId IdType="pmc">PMC11277692</ArticleId><ArticleId IdType="pubmed">39071889</ArticleId></ArticleIdList></Reference><Reference><Citation>Ray L.B. Lysosomal cholesterol activates mTORC1. Science. 2017;355:1277–1279. doi: 10.1126/science.355.6331.1277-q.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.355.6331.1277-q</ArticleId><ArticleId IdType="pubmed">28336650</ArticleId></ArticleIdList></Reference><Reference><Citation>Castellano B.M., Thelen A.M., Moldavski O., Feltes M., van der Welle R.E., Mydock-McGrane L., Jiang X., van Eijkeren R.J., Davis O.B., Louie S.M., et al. Lysosomal cholesterol activates mTORC1 via an SLC38A9-Niemann-Pick C1 signaling complex. Science. 2017;355:1306–1311. doi: 10.1126/science.aag1417.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aag1417</ArticleId><ArticleId IdType="pmc">PMC5823611</ArticleId><ArticleId IdType="pubmed">28336668</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramaiah M.J. mTOR inhibition and p53 activation, microRNAs: The possible therapy against pandemic COVID-19. Gene Rep. 2020;20:100765. doi: 10.1016/j.genrep.2020.100765.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.genrep.2020.100765</ArticleId><ArticleId IdType="pmc">PMC7324924</ArticleId><ArticleId IdType="pubmed">32835132</ArticleId></ArticleIdList></Reference><Reference><Citation>Elste J., Cast N., Udawatte S., Adhikari K., Payen S.H., Verma S.C., Shukla D., Swanson-Mungerson M., Tiwari V. Co-Expression of Niemann-Pick Type C1-Like1 (NPC1L1) with ACE2 Receptor Synergistically Enhances SARS-CoV-2 Entry and Fusion. Biomedicines. 2024;12:821. doi: 10.3390/biomedicines12040821.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines12040821</ArticleId><ArticleId IdType="pmc">PMC11048565</ArticleId><ArticleId IdType="pubmed">38672177</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudhop T., Reber M., Tribble D., Sapre A., Taggart W., Gibbons P., Musliner T., von Bergmann K., Lutjohann D. Changes in cholesterol absorption and cholesterol synthesis caused by ezetimibe and/or simvastatin in men. J. Lipid Res. 2009;50:2117–2123. doi: 10.1194/jlr.P900004-JLR200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1194/jlr.P900004-JLR200</ArticleId><ArticleId IdType="pmc">PMC2739752</ArticleId><ArticleId IdType="pubmed">19380898</ArticleId></ArticleIdList></Reference><Reference><Citation>Israel A., Schaffer A.A., Cicurel A., Cheng K., Sinha S., Schiff E., Feldhamer I., Tal A., Lavie G., Ruppin E. Identification of drugs associated with reduced severity of COVID-19—A case-control study in a large population. Elife. 2021;10:e68165. doi: 10.7554/eLife.68165.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.68165</ArticleId><ArticleId IdType="pmc">PMC8321549</ArticleId><ArticleId IdType="pubmed">34313216</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma-Lauer Y., Li P., Niemeyer D., Richter A., Pusl K., von Brunn B., Ru Y., Xiang C., Schwinghammer S., Liu J., et al. Oxysterole-binding protein targeted by SARS-CoV-2 viral proteins regulates coronavirus replication. Front. Cell Infect. Microbiol. 2024;14:1383917. doi: 10.3389/fcimb.2024.1383917.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcimb.2024.1383917</ArticleId><ArticleId IdType="pmc">PMC11306179</ArticleId><ArticleId IdType="pubmed">39119292</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagy P.D., Strating J.R., van Kuppeveld F.J. Building Viral Replication Organelles: Close Encounters of the Membrane Types. PLoS Pathog. 2016;12:e1005912. doi: 10.1371/journal.ppat.1005912.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1005912</ArticleId><ArticleId IdType="pmc">PMC5082816</ArticleId><ArticleId IdType="pubmed">27788266</ArticleId></ArticleIdList></Reference><Reference><Citation>Muller C., Hardt M., Schwudke D., Neuman B.W., Pleschka S., Ziebuhr J. Inhibition of Cytosolic Phospholipase A (2) alpha Impairs an Early Step of Coronavirus Replication in Cell Culture. J. Virol. 2018;92:e01463-17. doi: 10.1128/JVI.01463-17.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01463-17</ArticleId><ArticleId IdType="pmc">PMC5790932</ArticleId><ArticleId IdType="pubmed">29167338</ArticleId></ArticleIdList></Reference><Reference><Citation>Cubells L., Vila de Muga S., Tebar F., Bonventre J.V., Balsinde J., Pol A., Grewal T., Enrich C. Annexin A6-induced inhibition of cytoplasmic phospholipase A2 is linked to caveolin-1 export from the Golgi. J. Biol. Chem. 2008;283:10174–10183. doi: 10.1074/jbc.M706618200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M706618200</ArticleId><ArticleId IdType="pubmed">18245088</ArticleId></ArticleIdList></Reference><Reference><Citation>Mesquita F.S., Abrami L., Sergeeva O., Turelli P., Qing E., Kunz B., Raclot C., Paz Montoya J., Abriata L.A., Gallagher T., et al. S-acylation controls SARS-CoV-2 membrane lipid organization and enhances infectivity. Dev. Cell. 2021;56:2790–2807.e8. doi: 10.1016/j.devcel.2021.09.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.devcel.2021.09.016</ArticleId><ArticleId IdType="pmc">PMC8486083</ArticleId><ArticleId IdType="pubmed">34599882</ArticleId></ArticleIdList></Reference><Reference><Citation>Lenard J., Compans R.W. The membrane structure of lipid-containing viruses. Biochim. Biophys. Acta. 1974;344:51–94. doi: 10.1016/0304-4157(74)90008-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0304-4157(74)90008-2</ArticleId><ArticleId IdType="pmc">PMC7148776</ArticleId><ArticleId IdType="pubmed">4598854</ArticleId></ArticleIdList></Reference><Reference><Citation>Barman S., Nayak D.P. Lipid raft disruption by cholesterol depletion enhances influenza A virus budding from MDCK cells. J. Virol. 2007;81:12169–12178. doi: 10.1128/JVI.00835-07.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00835-07</ArticleId><ArticleId IdType="pmc">PMC2169012</ArticleId><ArticleId IdType="pubmed">17855515</ArticleId></ArticleIdList></Reference><Reference><Citation>Schloer S., Brunotte L., Goretzko J., Mecate-Zambrano A., Korthals N., Gerke V., Ludwig S., Rescher U. Targeting the endolysosomal host-SARS-CoV-2 interface by clinically licensed functional inhibitors of acid sphingomyelinase (FIASMA) including the antidepressant fluoxetine. Emerg. Microbes Infect. 2020;9:2245–2255. doi: 10.1080/22221751.2020.1829082.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2020.1829082</ArticleId><ArticleId IdType="pmc">PMC7594754</ArticleId><ArticleId IdType="pubmed">32975484</ArticleId></ArticleIdList></Reference><Reference><Citation>Nestel P.J. Cellular Control of Cholesterol-Metabolism. Pathology. 1978;10:184. doi: 10.1016/S0031-3025(16)38633-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0031-3025(16)38633-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Bays H.E., Kirkpatrick C.F., Maki K.C., Toth P.P., Morgan R.T., Tondt J., Christensen S.M., Dixon D.L., Jacobson T.A. Obesity, dyslipidemia, and cardiovascular disease: A joint expert review from the Obesity Medicine Association and the National Lipid Association 2024. J. Clin. Lipidol. 2024;18:e320–e350. doi: 10.1016/j.jacl.2024.04.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacl.2024.04.001</ArticleId><ArticleId IdType="pubmed">38664184</ArticleId></ArticleIdList></Reference><Reference><Citation>Buechler C., Aslanidis C. Role of lipids in pathophysiology, diagnosis and therapy of hepatocellular carcinoma. Biochim. Biophys. Acta Mol. Cell Biol. Lipids. 2020;1865:158658. doi: 10.1016/j.bbalip.2020.158658.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbalip.2020.158658</ArticleId><ArticleId IdType="pubmed">32058031</ArticleId></ArticleIdList></Reference><Reference><Citation>Hofmaenner D.A., Arina P., Kleyman A., Page Black L., Salomao R., Tanaka S., Guirgis F.W., Arulkumaran N., Singer M. Association Between Hypocholesterolemia and Mortality in Critically Ill Patients with Sepsis: A Systematic Review and Meta-Analysis. Crit. Care Explor. 2023;5:e0860. doi: 10.1097/CCE.0000000000000860.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCE.0000000000000860</ArticleId><ArticleId IdType="pmc">PMC9894355</ArticleId><ArticleId IdType="pubmed">36751516</ArticleId></ArticleIdList></Reference><Reference><Citation>Holven K.B., Roeters van Lennep J. Sex differences in lipids: A life course approach. Atherosclerosis. 2023;384:117270. doi: 10.1016/j.atherosclerosis.2023.117270.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.atherosclerosis.2023.117270</ArticleId><ArticleId IdType="pubmed">37730457</ArticleId></ArticleIdList></Reference><Reference><Citation>Massy Z.A., de Zeeuw D. LDL cholesterol in CKD--to treat or not to treat? Kidney Int. 2013;84:451–456. doi: 10.1038/ki.2013.181.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ki.2013.181</ArticleId><ArticleId IdType="pubmed">23698234</ArticleId></ArticleIdList></Reference><Reference><Citation>Luxenburger H., Thimme R. SARS-CoV-2 and the liver: Clinical and immunological features in chronic liver disease. Gut. 2023;72:1783–1794. doi: 10.1136/gutjnl-2023-329623.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2023-329623</ArticleId><ArticleId IdType="pmc">PMC10423489</ArticleId><ArticleId IdType="pubmed">37316169</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnes E. Infection of liver hepatocytes with SARS-CoV-2. Nat. Metab. 2022;4:301–302. doi: 10.1038/s42255-022-00554-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s42255-022-00554-4</ArticleId><ArticleId IdType="pubmed">35347317</ArticleId></ArticleIdList></Reference><Reference><Citation>Khovidhunkit W., Kim M.S., Memon R.A., Shigenaga J.K., Moser A.H., Feingold K.R., Grunfeld C. Effects of infection and inflammation on lipid and lipoprotein metabolism: Mechanisms and consequences to the host. J. Lipid Res. 2004;45:1169–1196. doi: 10.1194/jlr.R300019-JLR200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1194/jlr.R300019-JLR200</ArticleId><ArticleId IdType="pubmed">15102878</ArticleId></ArticleIdList></Reference><Reference><Citation>Buechler C., Bauer S. ATP binding cassette transporter A1 (ABCA1) associated proteins: Potential drug targets in the metabolic syndrome and atherosclerotic disease? Curr. Pharm. Biotechnol. 2012;13:319–330. doi: 10.2174/138920112799095365.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/138920112799095365</ArticleId><ArticleId IdType="pubmed">21470122</ArticleId></ArticleIdList></Reference><Reference><Citation>Helou M., Nasr J., El Osta N., Jabbour E., Husni R. Liver manifestations in COVID-19 patients: A review article. World J. Clin. Cases. 2023;11:2189–2200. doi: 10.12998/wjcc.v11.i10.2189.</Citation><ArticleIdList><ArticleId IdType="doi">10.12998/wjcc.v11.i10.2189</ArticleId><ArticleId IdType="pmc">PMC10131011</ArticleId><ArticleId IdType="pubmed">37122526</ArticleId></ArticleIdList></Reference><Reference><Citation>Strnad P., Tacke F., Koch A., Trautwein C. Liver–guardian, modifier and target of sepsis. Nat. Rev. Gastroenterol. Hepatol. 2017;14:55–66. doi: 10.1038/nrgastro.2016.168.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrgastro.2016.168</ArticleId><ArticleId IdType="pubmed">27924081</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y., Hu M., Yang H. Cirrhosis is an independent predictor for COVID-19 mortality: A meta-analysis of confounding cofactors-controlled data. J. Hepatol. 2023;78:e28–e31. doi: 10.1016/j.jhep.2022.09.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jhep.2022.09.015</ArticleId><ArticleId IdType="pmc">PMC9513401</ArticleId><ArticleId IdType="pubmed">36179997</ArticleId></ArticleIdList></Reference><Reference><Citation>Oh J.S., Choi J.S., Lee Y.H., Ko K.O., Lim J.W., Cheon E.J., Lee G.M., Yoon J.M. The Relationships between Respiratory Virus Infection and Aminotransferase in Children. Pediatr. Gastroenterol. Hepatol. Nutr. 2016;19:243–250. doi: 10.5223/pghn.2016.19.4.243.</Citation><ArticleIdList><ArticleId IdType="doi">10.5223/pghn.2016.19.4.243</ArticleId><ArticleId IdType="pmc">PMC5234413</ArticleId><ArticleId IdType="pubmed">28090469</ArticleId></ArticleIdList></Reference><Reference><Citation>Takemura K., Board P.G., Koga F. A Systematic Review of Serum gamma-Glutamyltransferase as a Prognostic Biomarker in Patients with Genitourinary Cancer. Antioxidants. 2021;10:549. doi: 10.3390/antiox10040549.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antiox10040549</ArticleId><ArticleId IdType="pmc">PMC8066142</ArticleId><ArticleId IdType="pubmed">33916150</ArticleId></ArticleIdList></Reference><Reference><Citation>Moon A.M., Barritt A.S., 4th Elevated Liver Enzymes in Patients with COVID-19: Look, but Not Too Hard. Dig. Dis. Sci. 2021;66:1767–1769. doi: 10.1007/s10620-020-06585-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10620-020-06585-9</ArticleId><ArticleId IdType="pmc">PMC7462733</ArticleId><ArticleId IdType="pubmed">32875529</ArticleId></ArticleIdList></Reference><Reference><Citation>Agarwal A., Chen A., Ravindran N., To C., Thuluvath P.J. Gastrointestinal and Liver Manifestations of COVID-19. J. Clin. Exp. Hepatol. 2020;10:263–265. doi: 10.1016/j.jceh.2020.03.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jceh.2020.03.001</ArticleId><ArticleId IdType="pmc">PMC7212283</ArticleId><ArticleId IdType="pubmed">32405183</ArticleId></ArticleIdList></Reference><Reference><Citation>Dietrich C.G., Geier A., Merle U. Non-alcoholic fatty liver disease and COVID-19: Harmless companions or disease intensifier? World J. Gastroenterol. 2023;29:367–377. doi: 10.3748/wjg.v29.i2.367.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v29.i2.367</ArticleId><ArticleId IdType="pmc">PMC9846932</ArticleId><ArticleId IdType="pubmed">36687116</ArticleId></ArticleIdList></Reference><Reference><Citation>Ekpanyapong S., Reddy K.R. Liver and Biliary Tract Disease in Patients with Coronavirus disease-2019 Infection. Gastroenterol. Clin. North. Am. 2023;52:13–36. doi: 10.1016/j.gtc.2022.09.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.gtc.2022.09.001</ArticleId><ArticleId IdType="pmc">PMC9531659</ArticleId><ArticleId IdType="pubmed">36813421</ArticleId></ArticleIdList></Reference><Reference><Citation>Jia C., Anderson J.L.C., Gruppen E.G., Lei Y., Bakker S.J.L., Dullaart R.P.F., Tietge U.J.F. High-Density Lipoprotein Anti-Inflammatory Capacity and Incident Cardiovascular Events. Circulation. 2021;143:1935–1945. doi: 10.1161/CIRCULATIONAHA.120.050808.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.120.050808</ArticleId><ArticleId IdType="pubmed">33840204</ArticleId></ArticleIdList></Reference><Reference><Citation>Trinder M., Walley K.R., Boyd J.H., Brunham L.R. Causal Inference for Genetically Determined Levels of High-Density Lipoprotein Cholesterol and Risk of Infectious Disease. Arter. Thromb. Vasc. Biol. 2020;40:267–278. doi: 10.1161/ATVBAHA.119.313381.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/ATVBAHA.119.313381</ArticleId><ArticleId IdType="pmc">PMC6946100</ArticleId><ArticleId IdType="pubmed">31694394</ArticleId></ArticleIdList></Reference><Reference><Citation>Grion C.M., Cardoso L.T., Perazolo T.F., Garcia A.S., Barbosa D.S., Morimoto H.K., Matsuo T., Carrilho A.J. Lipoproteins and CETP levels as risk factors for severe sepsis in hospitalized patients. Eur. J. Clin. Invest. 2010;40:330–338. doi: 10.1111/j.1365-2362.2010.02269.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2362.2010.02269.x</ArticleId><ArticleId IdType="pubmed">20486994</ArticleId></ArticleIdList></Reference><Reference><Citation>Stiekema L.C.A., Willemsen L., Kaiser Y., Prange K.H.M., Wareham N.J., Boekholdt S.M., Kuijk C., de Winther M.P.J., Voermans C., Nahrendorf M., et al. Impact of cholesterol on proinflammatory monocyte production by the bone marrow. Eur. Heart J. 2021;42:4309–4320. doi: 10.1093/eurheartj/ehab465.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehab465</ArticleId><ArticleId IdType="pmc">PMC8572558</ArticleId><ArticleId IdType="pubmed">34343254</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Banna N., Lehmann C. Oxidized LDL and LOX-1 in experimental sepsis. Mediat. Inflamm. 2013;2013:761789. doi: 10.1155/2013/761789.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2013/761789</ArticleId><ArticleId IdType="pmc">PMC3755390</ArticleId><ArticleId IdType="pubmed">24000272</ArticleId></ArticleIdList></Reference><Reference><Citation>Netea M.G., Demacker P.N., Kullberg B.J., Boerman O.C., Verschueren I., Stalenhoef A.F., van der Meer J.W. Low-density lipoprotein receptor-deficient mice are protected against lethal endotoxemia and severe gram-negative infections. J. Clin. Investig. 1996;97:1366–1372. doi: 10.1172/JCI118556.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI118556</ArticleId><ArticleId IdType="pmc">PMC507194</ArticleId><ArticleId IdType="pubmed">8617867</ArticleId></ArticleIdList></Reference><Reference><Citation>Booth A., Reed A.B., Ponzo S., Yassaee A., Aral M., Plans D., Labrique A., Mohan D. Population risk factors for severe disease and mortality in COVID-19: A global systematic review and meta-analysis. PLoS ONE. 2021;16:e0247461. doi: 10.1371/journal.pone.0247461.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0247461</ArticleId><ArticleId IdType="pmc">PMC7932512</ArticleId><ArticleId IdType="pubmed">33661992</ArticleId></ArticleIdList></Reference><Reference><Citation>Sieurin J., Branden G., Magnusson C., Hergens M.P., Kosidou K. A population-based cohort study of sex and risk of severe outcomes in COVID-19. Eur. J. Epidemiol. 2022;37:1159–1169. doi: 10.1007/s10654-022-00919-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10654-022-00919-9</ArticleId><ArticleId IdType="pmc">PMC9607822</ArticleId><ArticleId IdType="pubmed">36301399</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheidt-Nave C., Du Y., Knopf H., Schienkiewitz A., Ziese T., Nowossadeck E., Gösswald A., Busch M.A. Prevalence of dyslipidemia among adults in Germany. Results of the German Health Interview and Examination Survey for Adults (DEGS1) Bundesgesundheitsblatt-Gesundheitsforschung-Gesundheitsschutz. 2013;56:661–667. doi: 10.1007/s00103-013-1670-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00103-013-1670-0</ArticleId><ArticleId IdType="pubmed">23703484</ArticleId></ArticleIdList></Reference><Reference><Citation>Guadamuz J.S., Shooshtari A., Qato D.M. Global, regional and national trends in statin utilisation in high-income and low/middle-income countries, 2015–2020. BMJ Open. 2022;12:e061350. doi: 10.1136/bmjopen-2022-061350.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2022-061350</ArticleId><ArticleId IdType="pmc">PMC9462115</ArticleId><ArticleId IdType="pubmed">36691204</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y., Ashcroft T., Chung A., Dighero I., Dozier M., Horne M., McSwiggan E., Shamsuddin A., Nair H. Risk factors for poor outcomes in hospitalised COVID-19 patients: A systematic review and meta-analysis. J. Glob. Health. 2021;11:10001. doi: 10.7189/jogh.11.10001.</Citation><ArticleIdList><ArticleId IdType="doi">10.7189/jogh.11.10001</ArticleId><ArticleId IdType="pmc">PMC7980087</ArticleId><ArticleId IdType="pubmed">33767855</ArticleId></ArticleIdList></Reference><Reference><Citation>Grewal T., Buechler C. Adipokines as Diagnostic and Prognostic Markers for the Severity of COVID-19. Biomedicines. 2023;11:1302. doi: 10.3390/biomedicines11051302.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines11051302</ArticleId><ArticleId IdType="pmc">PMC10215701</ArticleId><ArticleId IdType="pubmed">37238973</ArticleId></ArticleIdList></Reference><Reference><Citation>Atmosudigdo I.S., Lim M.A., Radi B., Henrina J., Yonas E., Vania R., Pranata R. Dyslipidemia Increases the Risk of Severe COVID-19: A Systematic Review, Meta-analysis, and Meta-regression. Clin. Med. Insights Endocrinol. Diabetes. 2021;14:1179551421990675. doi: 10.1177/1179551421990675.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1179551421990675</ArticleId><ArticleId IdType="pmc">PMC8842489</ArticleId><ArticleId IdType="pubmed">35173508</ArticleId></ArticleIdList></Reference><Reference><Citation>Mostaza J.M., Salinero-Fort M.A., Cardenas-Valladolid J., Rodriguez-Artalejo F., Diaz-Almiron M., Vich-Perez P., San Andres-Rebollo F.J., Vicente I., Lahoz C. Pre-infection HDL-cholesterol levels and mortality among elderly patients infected with SARS-CoV-2. Atherosclerosis. 2022;341:13–19. doi: 10.1016/j.atherosclerosis.2021.12.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.atherosclerosis.2021.12.009</ArticleId><ArticleId IdType="pmc">PMC8692242</ArticleId><ArticleId IdType="pubmed">34959204</ArticleId></ArticleIdList></Reference><Reference><Citation>Hofmaenner D.A., Kleyman A., Press A., Bauer M., Singer M. The Many Roles of Cholesterol in Sepsis: A Review. Am. J. Respir. Crit. Care Med. 2022;205:388–396. doi: 10.1164/rccm.202105-1197TR.</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.202105-1197TR</ArticleId><ArticleId IdType="pmc">PMC8886946</ArticleId><ArticleId IdType="pubmed">34715007</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Wyngene L., Vandewalle J., Libert C. Reprogramming of basic metabolic pathways in microbial sepsis: Therapeutic targets at last? EMBO Mol. Med. 2018;10:e8712. doi: 10.15252/emmm.201708712.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/emmm.201708712</ArticleId><ArticleId IdType="pmc">PMC6079534</ArticleId><ArticleId IdType="pubmed">29976786</ArticleId></ArticleIdList></Reference><Reference><Citation>Zinellu A., Paliogiannis P., Fois A.G., Solidoro P., Carru C., Mangoni A.A. Cholesterol and Triglyceride Concentrations, COVID-19 Severity, and Mortality: A Systematic Review and Meta-Analysis with Meta-Regression. Front. Public. Health. 2021;9:705916. doi: 10.3389/fpubh.2021.705916.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpubh.2021.705916</ArticleId><ArticleId IdType="pmc">PMC8417431</ArticleId><ArticleId IdType="pubmed">34490188</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei X., Zeng W., Su J., Wan H., Yu X., Cao X., Tan W., Wang H. Hypolipidemia is associated with the severity of COVID-19. J. Clin. Lipidol. 2020;14:297–304. doi: 10.1016/j.jacl.2020.04.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacl.2020.04.008</ArticleId><ArticleId IdType="pmc">PMC7192140</ArticleId><ArticleId IdType="pubmed">32430154</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao M., Luo Z., He H., Shen B., Liang J., Zhang J., Ye J., Xu Y., Wang Z., Ye D., et al. Decreased Low-Density Lipoprotein Cholesterol Level Indicates Poor Prognosis of Severe and Critical COVID-19 Patients: A Retrospective, Single-Center Study. Front. Med. 2021;8:585851. doi: 10.3389/fmed.2021.585851.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2021.585851</ArticleId><ArticleId IdType="pmc">PMC8187559</ArticleId><ArticleId IdType="pubmed">34124081</ArticleId></ArticleIdList></Reference><Reference><Citation>Henriquez-Camacho C., Losa J. Biomarkers for sepsis. Biomed. Res. Int. 2014;2014:547818. doi: 10.1155/2014/547818.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2014/547818</ArticleId><ArticleId IdType="pmc">PMC3985161</ArticleId><ArticleId IdType="pubmed">24800240</ArticleId></ArticleIdList></Reference><Reference><Citation>Stasi A., Franzin R., Fiorentino M., Squiccimarro E., Castellano G., Gesualdo L. Multifaced Roles of HDL in Sepsis and SARS-CoV-2 Infection: Renal Implications. Int. J. Mol. Sci. 2021;22:5980. doi: 10.3390/ijms22115980.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22115980</ArticleId><ArticleId IdType="pmc">PMC8197836</ArticleId><ArticleId IdType="pubmed">34205975</ArticleId></ArticleIdList></Reference><Reference><Citation>Alkhouli M., Nanjundappa A., Annie F., Bates M.C., Bhatt D.L. Sex Differences in Case Fatality Rate of COVID-19: Insights from a Multinational Registry. Mayo Clin. Proc. 2020;95:1613–1620. doi: 10.1016/j.mayocp.2020.05.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mayocp.2020.05.014</ArticleId><ArticleId IdType="pmc">PMC7256502</ArticleId><ArticleId IdType="pubmed">32753136</ArticleId></ArticleIdList></Reference><Reference><Citation>Vahidy F.S., Pan A.P., Ahnstedt H., Munshi Y., Choi H.A., Tiruneh Y., Nasir K., Kash B.A., Andrieni J.D., McCullough L.D. Sex differences in susceptibility, severity, and outcomes of coronavirus disease 2019: Cross-sectional analysis from a diverse US metropolitan area. PLoS ONE. 2021;16:e0245556. doi: 10.1371/journal.pone.0245556.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0245556</ArticleId><ArticleId IdType="pmc">PMC7806140</ArticleId><ArticleId IdType="pubmed">33439908</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmisano B.T., Zhu L., Eckel R.H., Stafford J.M. Sex differences in lipid and lipoprotein metabolism. Mol. Metab. 2018;15:45–55. doi: 10.1016/j.molmet.2018.05.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molmet.2018.05.008</ArticleId><ArticleId IdType="pmc">PMC6066747</ArticleId><ArticleId IdType="pubmed">29858147</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu W., Guan H., Gao D., Pan J., Wang Z., Alam M., Lian J., Zhou J. Sex-specific association of monocyte count to high-density lipoprotein ratio with SYNTAX score in patients with suspected stable coronary artery disease. Medicine. 2019;98:e17536. doi: 10.1097/MD.0000000000017536.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MD.0000000000017536</ArticleId><ArticleId IdType="pmc">PMC6799519</ArticleId><ArticleId IdType="pubmed">31593130</ArticleId></ArticleIdList></Reference><Reference><Citation>Rauschert S., Uhl O., Koletzko B., Mori T.A., Beilin L.J., Oddy W.H., Hellmuth C. Sex differences in the association of phospholipids with components of the metabolic syndrome in young adults. Biol. Sex. Differ. 2017;8:10. doi: 10.1186/s13293-017-0131-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13293-017-0131-0</ArticleId><ArticleId IdType="pmc">PMC5371176</ArticleId><ArticleId IdType="pubmed">28360990</ArticleId></ArticleIdList></Reference><Reference><Citation>Peschel G., Grimm J., Muller M., Horing M., Krautbauer S., Weigand K., Liebisch G., Buechler C. Sex-specific changes in triglyceride profiles in liver cirrhosis and hepatitis C virus infection. Lipids Health Dis. 2022;21:106. doi: 10.1186/s12944-022-01715-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12944-022-01715-w</ArticleId><ArticleId IdType="pmc">PMC9590217</ArticleId><ArticleId IdType="pubmed">36280840</ArticleId></ArticleIdList></Reference><Reference><Citation>Escarcega R.D., Honarpisheh P., Colpo G.D., Ahnstedt H.W., Couture L., Juneja S., Torres G., Ortiz G.J., Sollome J., Tabor N., et al. Sex differences in global metabolomic profiles of COVID-19 patients. Cell Death Dis. 2022;13:461. doi: 10.1038/s41419-022-04861-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41419-022-04861-2</ArticleId><ArticleId IdType="pmc">PMC9106988</ArticleId><ArticleId IdType="pubmed">35568706</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurano M., Kano K., Hara M., Tsukamoto K., Aoki J., Yatomi Y. Regulation of plasma glycero-lysophospholipid levels by lipoprotein metabolism. Biochem. J. 2019;476:3565–3581. doi: 10.1042/BCJ20190498.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/BCJ20190498</ArticleId><ArticleId IdType="pubmed">31746967</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan S.T., Ramesh T., Toh X.R., Nguyen L.N. Emerging roles of lysophospholipids in health and disease. Prog. Lipid Res. 2020;80:101068. doi: 10.1016/j.plipres.2020.101068.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.plipres.2020.101068</ArticleId><ArticleId IdType="pubmed">33068601</ArticleId></ArticleIdList></Reference><Reference><Citation>Duong C.Q., Bared S.M., Abu-Khader A., Buechler C., Schmitz A., Schmitz G. Expression of the lysophospholipid receptor family and investigation of lysophospholipid-mediated responses in human macrophages. Biochim. Biophys. Acta. 2004;1682:112–119. doi: 10.1016/j.bbalip.2004.03.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbalip.2004.03.002</ArticleId><ArticleId IdType="pubmed">15158762</ArticleId></ArticleIdList></Reference><Reference><Citation>Graler M.H., Goetzl E.J. Lysophospholipids and their G protein-coupled receptors in inflammation and immunity. Biochim. Biophys. Acta. 2002;1582:168–174. doi: 10.1016/S1388-1981(02)00152-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1388-1981(02)00152-X</ArticleId><ArticleId IdType="pubmed">12069825</ArticleId></ArticleIdList></Reference><Reference><Citation>Bozelli J.C., Jr., Azher S., Epand R.M. Plasmalogens and Chronic Inflammatory Diseases. Front. Physiol. 2021;12:730829. doi: 10.3389/fphys.2021.730829.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphys.2021.730829</ArticleId><ArticleId IdType="pmc">PMC8566352</ArticleId><ArticleId IdType="pubmed">34744771</ArticleId></ArticleIdList></Reference><Reference><Citation>Godlewska U., Bulanda E., Wypych T.P. Bile acids in immunity: Bidirectional mediators between the host and the microbiota. Front. Immunol. 2022;13:949033. doi: 10.3389/fimmu.2022.949033.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.949033</ArticleId><ArticleId IdType="pmc">PMC9425027</ArticleId><ArticleId IdType="pubmed">36052074</ArticleId></ArticleIdList></Reference><Reference><Citation>Valdes A., Moreno L.O., Rello S.R., Orduna A., Bernardo D., Cifuentes A. Metabolomics study of COVID-19 patients in four different clinical stages. Sci. Rep. 2022;12:1650. doi: 10.1038/s41598-022-05667-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-022-05667-0</ArticleId><ArticleId IdType="pmc">PMC8803913</ArticleId><ArticleId IdType="pubmed">35102215</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang X., Liu X., Li Z. Bile acids and coronavirus disease 2019. Acta. Pharm. Sin. B. 2024;14:1939–1950. doi: 10.1016/j.apsb.2024.02.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.apsb.2024.02.011</ArticleId><ArticleId IdType="pmc">PMC11119507</ArticleId><ArticleId IdType="pubmed">38799626</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel P.N., Shah R.Y., Ferguson J.F., Reilly M.P. Human experimental endotoxemia in modeling the pathophysiology, genomics, and therapeutics of innate immunity in complex cardiometabolic diseases. Arter. Thromb. Vasc. Biol. 2015;35:525–534. doi: 10.1161/ATVBAHA.114.304455.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/ATVBAHA.114.304455</ArticleId><ArticleId IdType="pmc">PMC4344396</ArticleId><ArticleId IdType="pubmed">25550206</ArticleId></ArticleIdList></Reference><Reference><Citation>Marcello A., Civra A., Milan Bonotto R., Nascimento Alves L., Rajasekharan S., Giacobone C., Caccia C., Cavalli R., Adami M., Brambilla P., et al. The cholesterol metabolite 27-hydroxycholesterol inhibits SARS-CoV-2 and is markedly decreased in COVID-19 patients. Redox Biol. 2020;36:101682. doi: 10.1016/j.redox.2020.101682.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.redox.2020.101682</ArticleId><ArticleId IdType="pmc">PMC7416714</ArticleId><ArticleId IdType="pubmed">32810737</ArticleId></ArticleIdList></Reference><Reference><Citation>Saballs S.M., Parra S., Martinez N., Amigo N., Cabau L., Iftimie S., Pavon R., Gavaldo X., Correig X., Paredes S., et al. Lipidomic and Metabolomic Changes in Community-acquired and COVID-19 Pneumonia. J. Lipid Res. 2024;65:100622. doi: 10.1016/j.jlr.2024.100622.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jlr.2024.100622</ArticleId><ArticleId IdType="pmc">PMC11422144</ArticleId><ArticleId IdType="pubmed">39154734</ArticleId></ArticleIdList></Reference><Reference><Citation>Li G., Du L., Cao X., Wei X., Jiang Y., Lin Y., Nguyen V., Tan W., Wang H. Follow-up study on serum cholesterol profiles and potential sequelae in recovered COVID-19 patients. BMC Infect. Dis. 2021;21:299. doi: 10.1186/s12879-021-05984-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-021-05984-1</ArticleId><ArticleId IdType="pmc">PMC7989719</ArticleId><ArticleId IdType="pubmed">33761881</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu E., Xie Y., Al-Aly Z. Risks and burdens of incident dyslipidaemia in long COVID: A cohort study. Lancet Diabetes Endocrinol. 2023;11:120–128. doi: 10.1016/S2213-8587(22)00355-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-8587(22)00355-2</ArticleId><ArticleId IdType="pmc">PMC9873268</ArticleId><ArticleId IdType="pubmed">36623520</ArticleId></ArticleIdList></Reference><Reference><Citation>Mietus-Snyder M., Suslovic W., Delaney M., Playford M.P., Ballout R.A., Barber J.R., Otvos J.D., DeBiasi R.L., Mehta N.N., Remaley A.T. Changes in HDL cholesterol, particles, and function associate with pediatric COVID-19 severity. Front. Cardiovasc. Med. 2022;9:1033660. doi: 10.3389/fcvm.2022.1033660.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcvm.2022.1033660</ArticleId><ArticleId IdType="pmc">PMC9597312</ArticleId><ArticleId IdType="pubmed">36312284</ArticleId></ArticleIdList></Reference><Reference><Citation>Uysal P., Yuksel A., Durmus S., Cuhadaroglu C., Gelisgen R., Uzun H. Can circulating oxidative stress-related biomarkers be used as an early prognostic marker for COVID-19? Front. Med. 2023;10:1041115. doi: 10.3389/fmed.2023.1041115.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2023.1041115</ArticleId><ArticleId IdType="pmc">PMC9948026</ArticleId><ArticleId IdType="pubmed">36844214</ArticleId></ArticleIdList></Reference><Reference><Citation>Lavis P., Morra S., Orte Cano C., Albayrak N., Corbiere V., Olislagers V., Dauby N., Del Marmol V., Marchant A., Decaestecker C., et al. Chemerin plasma levels are increased in COVID-19 patients and are an independent risk factor of mortality. Front. Immunol. 2022;13:941663. doi: 10.3389/fimmu.2022.941663.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.941663</ArticleId><ArticleId IdType="pmc">PMC9412239</ArticleId><ArticleId IdType="pubmed">36032171</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang Y., Liu L., Liang B. COVID-19 susceptibility and severity for dyslipidemia: A mendelian randomization investigation. Heliyon. 2023;9:e20247. doi: 10.1016/j.heliyon.2023.e20247.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.heliyon.2023.e20247</ArticleId><ArticleId IdType="pmc">PMC10560011</ArticleId><ArticleId IdType="pubmed">37809746</ArticleId></ArticleIdList></Reference><Reference><Citation>Kazenwadel J., Berezhnoy G., Cannet C., Schafer H., Geisler T., Rohlfing A.K., Gawaz M., Merle U., Trautwein C. Stratification of hypertension and SARS-CoV-2 infection by quantitative NMR spectroscopy of human blood serum. Commun. Med. 2023;3:145. doi: 10.1038/s43856-023-00365-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s43856-023-00365-y</ArticleId><ArticleId IdType="pmc">PMC11081957</ArticleId><ArticleId IdType="pubmed">37845506</ArticleId></ArticleIdList></Reference><Reference><Citation>Caterino M., Gelzo M., Sol S., Fedele R., Annunziata A., Calabrese C., Fiorentino G., D’Abbraccio M., Dell’Isola C., Fusco F.M., et al. Dysregulation of lipid metabolism and pathological inflammation in patients with COVID-19. Sci. Rep. 2021;11:2941. doi: 10.1038/s41598-021-82426-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-82426-7</ArticleId><ArticleId IdType="pmc">PMC7859398</ArticleId><ArticleId IdType="pubmed">33536486</ArticleId></ArticleIdList></Reference><Reference><Citation>Mester P., Amend P., Schmid S., Muller M., Buechler C., Pavel V. Plasma Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) as a Possible Biomarker for Severe COVID-19. Viruses. 2023;15:1511. doi: 10.3390/v15071511.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v15071511</ArticleId><ArticleId IdType="pmc">PMC10385877</ArticleId><ArticleId IdType="pubmed">37515197</ArticleId></ArticleIdList></Reference><Reference><Citation>Grewal T., Buechler C. Emerging Insights on the Diverse Roles of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in Chronic Liver Diseases: Cholesterol Metabolism and Beyond. Int. J. Mol. Sci. 2022;23:1070. doi: 10.3390/ijms23031070.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms23031070</ArticleId><ArticleId IdType="pmc">PMC8834914</ArticleId><ArticleId IdType="pubmed">35162992</ArticleId></ArticleIdList></Reference><Reference><Citation>Behl T., Kaur I., Aleya L., Sehgal A., Singh S., Sharma N., Bhatia S., Al-Harrasi A., Bungau S. CD147-spike protein interaction in COVID-19: Get the ball rolling with a novel receptor and therapeutic target. Sci. Total Environ. 2022;808:152072. doi: 10.1016/j.scitotenv.2021.152072.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.scitotenv.2021.152072</ArticleId><ArticleId IdType="pmc">PMC8634688</ArticleId><ArticleId IdType="pubmed">34863742</ArticleId></ArticleIdList></Reference><Reference><Citation>Bakillah A., Hejji F.A., Almasaud A., Jami H.A., Hawwari A., Qarni A.A., Iqbal J., Alharbi N.K. Lipid Raft Integrity and Cellular Cholesterol Homeostasis Are Critical for SARS-CoV-2 Entry into Cells. Nutrients. 2022;14:3417. doi: 10.3390/nu14163417.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu14163417</ArticleId><ArticleId IdType="pmc">PMC9415163</ArticleId><ArticleId IdType="pubmed">36014919</ArticleId></ArticleIdList></Reference><Reference><Citation>Fiore D., Proto M.C., Franceschelli S., Pascale M., Bifulco M., Gazzerro P. In Vitro Evidence of Statins’ Protective Role against COVID-19 Hallmarks. Biomedicines. 2022;10:2123. doi: 10.3390/biomedicines10092123.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines10092123</ArticleId><ArticleId IdType="pmc">PMC9495908</ArticleId><ArticleId IdType="pubmed">36140223</ArticleId></ArticleIdList></Reference><Reference><Citation>Teixeira L., Temerozo J.R., Pereira-Dutra F.S., Ferreira A.C., Mattos M., Goncalves B.S., Sacramento C.Q., Palhinha L., Cunha-Fernandes T., Dias S.S.G., et al. Simvastatin Downregulates the SARS-CoV-2-Induced Inflammatory Response and Impairs Viral Infection Through Disruption of Lipid Rafts. Front. Immunol. 2022;13:820131. doi: 10.3389/fimmu.2022.820131.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.820131</ArticleId><ArticleId IdType="pmc">PMC8895251</ArticleId><ArticleId IdType="pubmed">35251001</ArticleId></ArticleIdList></Reference><Reference><Citation>De Spiegeleer A., Bronselaer A., Teo J.T., Byttebier G., De Tre G., Belmans L., Dobson R., Wynendaele E., Van De Wiele C., Vandaele F., et al. The Effects of ARBs, ACEis, and Statins on Clinical Outcomes of COVID-19 Infection Among Nursing Home Residents. J. Am. Med. Dir. Assoc. 2020;21:909–914.e2. doi: 10.1016/j.jamda.2020.06.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jamda.2020.06.018</ArticleId><ArticleId IdType="pmc">PMC7294267</ArticleId><ArticleId IdType="pubmed">32674818</ArticleId></ArticleIdList></Reference><Reference><Citation>Silhol F., Sarlon G., Deharo J.C., Vaisse B. Downregulation of ACE2 induces overstimulation of the renin-angiotensin system in COVID-19: Should we block the renin-angiotensin system? Hypertens. Res. 2020;43:854–856. doi: 10.1038/s41440-020-0476-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41440-020-0476-3</ArticleId><ArticleId IdType="pmc">PMC7242178</ArticleId><ArticleId IdType="pubmed">32439915</ArticleId></ArticleIdList></Reference><Reference><Citation>Sasidhar M.V., Chevooru S.K., Eickelberg O., Hartung H.P., Neuhaus O. Downregulation of monocytic differentiation via modulation of CD147 by 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. PLoS ONE. 2017;12:e0189701. doi: 10.1371/journal.pone.0189701.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0189701</ArticleId><ArticleId IdType="pmc">PMC5734787</ArticleId><ArticleId IdType="pubmed">29253870</ArticleId></ArticleIdList></Reference><Reference><Citation>Zivkovic S., Maric G., Cvetinovic N., Lepojevic-Stefanovic D., Bozic Cvijan B. Anti-Inflammatory Effects of Lipid-Lowering Drugs and Supplements-A Narrative Review. Nutrients. 2023;15:1517. doi: 10.3390/nu15061517.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu15061517</ArticleId><ArticleId IdType="pmc">PMC10053759</ArticleId><ArticleId IdType="pubmed">36986246</ArticleId></ArticleIdList></Reference><Reference><Citation>Smaldone C., Brugaletta S., Pazzano V., Liuzzo G. Immunomodulator activity of 3-hydroxy-3-methilglutaryl-CoA inhibitors. Cardiovasc. Hematol. Agents Med. Chem. 2009;7:279–294. doi: 10.2174/187152509789541864.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/187152509789541864</ArticleId><ArticleId IdType="pubmed">19663791</ArticleId></ArticleIdList></Reference><Reference><Citation>Oliveira-Nascimento L., Massari P., Wetzler L.M. The Role of TLR2 in Infection and Immunity. Front. Immunol. 2012;3:79. doi: 10.3389/fimmu.2012.00079.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2012.00079</ArticleId><ArticleId IdType="pmc">PMC3342043</ArticleId><ArticleId IdType="pubmed">22566960</ArticleId></ArticleIdList></Reference><Reference><Citation>Hilgendorff A., Muth H., Parviz B., Staubitz A., Haberbosch W., Tillmanns H., Holschermann H. Statins differ in their ability to block NF-kappaB activation in human blood monocytes. Int. J. Clin. Pharmacol. Ther. 2003;41:397–401. doi: 10.5414/CPP41397.</Citation><ArticleIdList><ArticleId IdType="doi">10.5414/CPP41397</ArticleId><ArticleId IdType="pubmed">14518599</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng H.B., Libby P., Liao J.K. Induction and stabilization of I kappa B alpha by nitric oxide mediates inhibition of NF-kappa B. J. Biol. Chem. 1995;270:14214–14219. doi: 10.1074/jbc.270.23.14214.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.270.23.14214</ArticleId><ArticleId IdType="pubmed">7775482</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamamoto A., Hoshi K., Ichihara K. Fluvastatin, an inhibitor of 3-hydroxy-3-methylglutaryl-CoA reductase, scavenges free radicals and inhibits lipid peroxidation in rat liver microsomes. Eur. J. Pharmacol. 1998;361:143–149. doi: 10.1016/S0014-2999(98)00692-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0014-2999(98)00692-X</ArticleId><ArticleId IdType="pubmed">9851551</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrari F., Martins V.M., Teixeira M., Santos R.D., Stein R. COVID-19 and Thromboinflammation: Is There a Role for Statins? Clinics. 2021;76:e2518. doi: 10.6061/clinics/2021/e2518.</Citation><ArticleIdList><ArticleId IdType="doi">10.6061/clinics/2021/e2518</ArticleId><ArticleId IdType="pmc">PMC7955154</ArticleId><ArticleId IdType="pubmed">33787678</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiner Z., Hatamipour M., Banach M., Pirro M., Al-Rasadi K., Jamialahmadi T., Radenkovic D., Montecucco F., Sahebkar A. Statins and the COVID-19 main protease: In silico evidence on direct interaction. Arch. Med. Sci. 2020;16:490–496. doi: 10.5114/aoms.2020.94655.</Citation><ArticleIdList><ArticleId IdType="doi">10.5114/aoms.2020.94655</ArticleId><ArticleId IdType="pmc">PMC7212226</ArticleId><ArticleId IdType="pubmed">32399094</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghosh D., Ghosh Dastidar D., Roy K., Ghosh A., Mukhopadhyay D., Sikdar N., Biswas N.K., Chakrabarti G., Das A. Computational prediction of the molecular mechanism of statin group of drugs against SARS-CoV-2 pathogenesis. Sci. Rep. 2022;12:6241. doi: 10.1038/s41598-022-09845-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-022-09845-y</ArticleId><ArticleId IdType="pmc">PMC9009757</ArticleId><ArticleId IdType="pubmed">35422113</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y., Ku H., Zhao L., Wheeler D.C., Li L.C., Li Q., Varghese Z., Moorhead J.F., Powis S.H., Huang A., et al. Inflammatory stress induces statin resistance by disrupting 3-hydroxy-3-methylglutaryl-CoA reductase feedback regulation. Arter. Thromb. Vasc. Biol. 2014;34:365–376. doi: 10.1161/ATVBAHA.113.301301.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/ATVBAHA.113.301301</ArticleId><ArticleId IdType="pubmed">24233489</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y., Ruan X.Z., Li Q., Huang A., Moorhead J.F., Powis S.H., Varghese Z. Inflammatory cytokines disrupt LDL-receptor feedback regulation and cause statin resistance: A comparative study in human hepatic cells and mesangial cells. Am. J. Physiol. Ren. Physiol. 2007;293:F680–F687. doi: 10.1152/ajprenal.00209.2007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajprenal.00209.2007</ArticleId><ArticleId IdType="pubmed">17634396</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmadi Y., Fard J.K., Ghafoor D., Eid A.H., Sahebkar A. Paradoxical effects of statins on endothelial and cancer cells: The impact of concentrations. Cancer Cell Int. 2023;23:43. doi: 10.1186/s12935-023-02890-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12935-023-02890-1</ArticleId><ArticleId IdType="pmc">PMC9999585</ArticleId><ArticleId IdType="pubmed">36899388</ArticleId></ArticleIdList></Reference><Reference><Citation>Hussien N.R., Al-Niemi M.S., Al-Kuraishy H.M., Al-Gareeb A.I. Statins and COVID-19: The Neglected Front of bidirectional effects. J. Pak. Med. Assoc. 2021;7((Suppl. S8)):133–136.</Citation><ArticleIdList><ArticleId IdType="pubmed">35130236</ArticleId></ArticleIdList></Reference><Reference><Citation>Tani S., Takahashi A., Nagao K., Hirayama A. Contribution of apolipoprotein A-I to the reduction in high-sensitivity C-reactive protein levels by different statins: Comparative study of pitavastatin and atorvastatin. Heart Vessel. 2015;30:762–770. doi: 10.1007/s00380-014-0554-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00380-014-0554-z</ArticleId><ArticleId IdType="pubmed">25062713</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan Y.J., Li Y., Lou B., Wu M.P. Beneficial effects of ApoA-I on LPS-induced acute lung injury and endotoxemia in mice. Life Sci. 2006;79:210–215. doi: 10.1016/j.lfs.2006.02.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lfs.2006.02.011</ArticleId><ArticleId IdType="pubmed">16574162</ArticleId></ArticleIdList></Reference><Reference><Citation>Buechler C., Pohl R., Aslanidis C. Pro-Resolving Molecules-New Approaches to Treat Sepsis? Int. J. Mol. Sci. 2017;18:476. doi: 10.3390/ijms18030476.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms18030476</ArticleId><ArticleId IdType="pmc">PMC5372492</ArticleId><ArticleId IdType="pubmed">28241480</ArticleId></ArticleIdList></Reference><Reference><Citation>Nedeva C., Menassa J., Puthalakath H. Sepsis: Inflammation Is a Necessary Evil. Front. Cell Dev. Biol. 2019;7:108. doi: 10.3389/fcell.2019.00108.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcell.2019.00108</ArticleId><ArticleId IdType="pmc">PMC6596337</ArticleId><ArticleId IdType="pubmed">31281814</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen L., Qiu L., Wang L., Huang H., Liu D., Xiao Y., Liu Y., Jin J., Liu X., Wang D.W., et al. Statin Use and In-hospital Mortality in Patients with COVID-19 and Coronary Heart Disease. Sci. Rep. 2021;11:23874. doi: 10.1038/s41598-021-02534-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-02534-2</ArticleId><ArticleId IdType="pmc">PMC8668894</ArticleId><ArticleId IdType="pubmed">34903765</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadeghdoust M., Aligolighasemabadi F., Dehesh T., Taefehshokr N., Sadeghdoust A., Kotfis K., Hashemiattar A., Ravandi A., Aligolighasemabadi N., Vakili O., et al. The Effects of Statins on Respiratory Symptoms and Pulmonary Fibrosis in COVID-19 Patients with Diabetes Mellitus: A Longitudinal Multicenter Study. Arch. Immunol. Ther. Exp. 2023;71:8. doi: 10.1007/s00005-023-00672-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00005-023-00672-1</ArticleId><ArticleId IdType="pmc">PMC9972324</ArticleId><ArticleId IdType="pubmed">36853269</ArticleId></ArticleIdList></Reference><Reference><Citation>McAlister F.A., Wang T., Wang X., Chu A., Goodman S.G., van Diepen S., Jackevicius C.A., Kaul P., Udell J., Ko D.T., et al. Statins and SARS-CoV-2 Infection: Results of a Population-Based Prospective Cohort Study of 469 749 Adults from 2 Canadian Provinces. J. Am. Heart Assoc. 2021;10:e022330. doi: 10.1161/JAHA.121.022330.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/JAHA.121.022330</ArticleId><ArticleId IdType="pmc">PMC8751814</ArticleId><ArticleId IdType="pubmed">34689613</ArticleId></ArticleIdList></Reference><Reference><Citation>Bouillon K., Baricault B., Semenzato L., Botton J., Bertrand M., Drouin J., Dray-Spira R., Weill A., Zureik M. Association of Statins for Primary Prevention of Cardiovascular Diseases with Hospitalization for COVID-19: A Nationwide Matched Population-Based Cohort Study. J. Am. Heart Assoc. 2022;11:e023357. doi: 10.1161/JAHA.121.023357.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/JAHA.121.023357</ArticleId><ArticleId IdType="pmc">PMC9238639</ArticleId><ArticleId IdType="pubmed">35699173</ArticleId></ArticleIdList></Reference><Reference><Citation>Golomb B.A., Han J.H., Langsjoen P.H., Dinkeloo E., Zemljic-Harpf A.E. Statin Use in Relation to COVID-19 and Other Respiratory Infections: Muscle and Other Considerations. J. Clin. Med. 2023;12:4659. doi: 10.3390/jcm12144659.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm12144659</ArticleId><ArticleId IdType="pmc">PMC10380486</ArticleId><ArticleId IdType="pubmed">37510774</ArticleId></ArticleIdList></Reference><Reference><Citation>Pienkos S.M., Moore A.R., Guan J., Levitt J.E., Matthay M.A., Baron R.M., Conlon J., McAuley D.F., O’Kane C.M., Rogers A.J. Effect of total cholesterol and statin therapy on mortality in ARDS patients: A secondary analysis of the SAILS and HARP-2 trials. Crit. Care. 2023;27:126. doi: 10.1186/s13054-023-04387-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-023-04387-9</ArticleId><ArticleId IdType="pmc">PMC10053133</ArticleId><ArticleId IdType="pubmed">36978134</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim S.W., Kang H.J., Jhon M., Kim J.W., Lee J.Y., Walker A.J., Agustini B., Kim J.M., Berk M. Statins and Inflammation: New Therapeutic Opportunities in Psychiatry. Front. Psychiatry. 2019;10:103. doi: 10.3389/fpsyt.2019.00103.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpsyt.2019.00103</ArticleId><ArticleId IdType="pmc">PMC6413672</ArticleId><ArticleId IdType="pubmed">30890971</ArticleId></ArticleIdList></Reference><Reference><Citation>Sundararaman S.S., Doring Y., van der Vorst E.P.C. PCSK9: A Multi-Faceted Protein That Is Involved in Cardiovascular Biology. Biomedicines. 2021;9:793. doi: 10.3390/biomedicines9070793.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines9070793</ArticleId><ArticleId IdType="pmc">PMC8301306</ArticleId><ArticleId IdType="pubmed">34356856</ArticleId></ArticleIdList></Reference><Reference><Citation>Dubuc G., Chamberland A., Wassef H., Davignon J., Seidah N.G., Bernier L., Prat A. Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia. Arter. Thromb. Vasc. Biol. 2004;24:1454–1459. doi: 10.1161/01.ATV.0000134621.14315.43.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.ATV.0000134621.14315.43</ArticleId><ArticleId IdType="pubmed">15178557</ArticleId></ArticleIdList></Reference><Reference><Citation>Nozue T. Lipid Lowering Therapy and Circulating PCSK9 Concentration. J. Atheroscler. Thromb. 2017;24:895–907. doi: 10.5551/jat.RV17012.</Citation><ArticleIdList><ArticleId IdType="doi">10.5551/jat.RV17012</ArticleId><ArticleId IdType="pmc">PMC5587514</ArticleId><ArticleId IdType="pubmed">28804094</ArticleId></ArticleIdList></Reference><Reference><Citation>Dwivedi D.J., Grin P.M., Khan M., Prat A., Zhou J., Fox-Robichaud A.E., Seidah N.G., Liaw P.C. Differential Expression of PCSK9 Modulates Infection, Inflammation, and Coagulation in a Murine Model of Sepsis. Shock. 2016;46:672–680. doi: 10.1097/SHK.0000000000000682.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SHK.0000000000000682</ArticleId><ArticleId IdType="pubmed">27405064</ArticleId></ArticleIdList></Reference><Reference><Citation>Lei L., Li X., Yuan Y.J., Chen Z.L., He J.H., Wu J.H., Cai X.S. Inhibition of proprotein convertase subtilisin/kexin type 9 attenuates 2,4,6-trinitrobenzenesulfonic acid-induced colitis via repressing toll-like receptor 4/nuclear factor-kappa B. Kaohsiung J. Med. Sci. 2020;36:705–711. doi: 10.1002/kjm2.12225.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/kjm2.12225</ArticleId><ArticleId IdType="pubmed">32396274</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyd J.H., Fjell C.D., Russell J.A., Sirounis D., Cirstea M.S., Walley K.R. Increased Plasma PCSK9 Levels Are Associated with Reduced Endotoxin Clearance and the Development of Acute Organ Failures during Sepsis. J. Innate Immun. 2016;8:211–220. doi: 10.1159/000442976.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000442976</ArticleId><ArticleId IdType="pmc">PMC6738828</ArticleId><ArticleId IdType="pubmed">26756586</ArticleId></ArticleIdList></Reference><Reference><Citation>Walley K.R., Thain K.R., Russell J.A., Reilly M.P., Meyer N.J., Ferguson J.F., Christie J.D., Nakada T.A., Fjell C.D., Thair S.A., et al. PCSK9 is a critical regulator of the innate immune response and septic shock outcome. Sci. Transl. Med. 2014;6:258ra143. doi: 10.1126/scitranslmed.3008782.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.3008782</ArticleId><ArticleId IdType="pmc">PMC4342147</ArticleId><ArticleId IdType="pubmed">25320235</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitchell K.A., Moore J.X., Rosenson R.S., Irvin R., Guirgis F.W., Shapiro N., Safford M., Wang H.E. PCSK9 loss-of-function variants and risk of infection and sepsis in the Reasons for Geographic and Racial Differences in Stroke (REGARDS) cohort. PLoS ONE. 2019;14:e0210808. doi: 10.1371/journal.pone.0210808.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0210808</ArticleId><ArticleId IdType="pmc">PMC6364964</ArticleId><ArticleId IdType="pubmed">30726226</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Z., Zhang W., Burgner D., Tonkin A., Zhu C., Sun C., Magnussen C.G., Ernst M.E., Breslin M., Nicholls S.J., et al. The association between PCSK9 inhibitor use and sepsis—A systematic review and meta-analysis of 20 double-blind, randomized, placebo-controlled trials. Am. J. Med. 2023;136:558–567. doi: 10.1016/j.amjmed.2023.02.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjmed.2023.02.025</ArticleId><ArticleId IdType="pubmed">36921646</ArticleId></ArticleIdList></Reference><Reference><Citation>Scalise V., Sanguinetti C., Neri T., Cianchetti S., Lai M., Carnicelli V., Celi A., Pedrinelli R. PCSK9 Induces Tissue Factor Expression by Activation of TLR4/NFkB Signaling. Int. J. Mol. Sci. 2021;22:12640. doi: 10.3390/ijms222312640.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms222312640</ArticleId><ArticleId IdType="pmc">PMC8657476</ArticleId><ArticleId IdType="pubmed">34884442</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu X., Bao X., Hu M., Chang H., Jiao M., Cheng J., Xie L., Huang Q., Li F., Li C.Y. Inhibition of PCSK9 potentiates immune checkpoint therapy for cancer. Nature. 2020;588:693–698. doi: 10.1038/s41586-020-2911-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2911-7</ArticleId><ArticleId IdType="pmc">PMC7770056</ArticleId><ArticleId IdType="pubmed">33177715</ArticleId></ArticleIdList></Reference><Reference><Citation>Moriyama M., Lucas C., Monteiro V.S., Yale SARS-CoV-2 Genomic Surveillance Initiative. Iwasaki A. Enhanced inhibition of MHC-I expression by SARS-CoV-2 Omicron subvariants. Proc. Natl. Acad. Sci. USA. 2023;120:e2221652120. doi: 10.1073/pnas.2221652120.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2221652120</ArticleId><ArticleId IdType="pmc">PMC10120007</ArticleId><ArticleId IdType="pubmed">37036977</ArticleId></ArticleIdList></Reference><Reference><Citation>Navarese E.P., Podhajski P., Gurbel P.A., Grzelakowska K., Ruscio E., Tantry U., Magielski P., Kubica A., Niezgoda P., Adamski P., et al. PCSK9 Inhibition During the Inflammatory Stage of SARS-CoV-2 Infection. J. Am. Coll. Cardiol. 2023;81:224–234. doi: 10.1016/j.jacc.2022.10.030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2022.10.030</ArticleId><ArticleId IdType="pmc">PMC9842071</ArticleId><ArticleId IdType="pubmed">36653090</ArticleId></ArticleIdList></Reference><Reference><Citation>Elahi R., Hozhabri S., Moradi A., Siahmansouri A., Jahani Maleki A., Esmaeilzadeh A. Targeting the cGAS-STING pathway as an inflammatory crossroad in coronavirus disease 2019 (COVID-19) Immunopharmacol. Immunotoxicol. 2023;45:639–649. doi: 10.1080/08923973.2023.2215405.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/08923973.2023.2215405</ArticleId><ArticleId IdType="pubmed">37335770</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee W., Ahn J.H., Park H.H., Kim H.N., Kim H., Yoo Y., Shin H., Hong K.S., Jang J.G., Park C.G., et al. COVID-19-activated SREBP2 disturbs cholesterol biosynthesis and leads to cytokine storm. Signal Transduct. Target. Ther. 2020;5:186. doi: 10.1038/s41392-020-00292-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-020-00292-7</ArticleId><ArticleId IdType="pmc">PMC7471497</ArticleId><ArticleId IdType="pubmed">32883951</ArticleId></ArticleIdList></Reference><Reference><Citation>Mester P., Amend P., Schmid S., Wenzel J.J., Horing M., Liebisch G., Krautbauer S., Muller M., Buechler C., Pavel V. Proprotein Convertase Subtilisin/Kexin Type 9 Induction in COVID-19 Is Poorly Associated with Disease Severity and Cholesterol Levels. Infect. Dis. Rep. 2024;16:593–607. doi: 10.3390/idr16040045.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/idr16040045</ArticleId><ArticleId IdType="pmc">PMC11270413</ArticleId><ArticleId IdType="pubmed">39051245</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang W., Xiao J., Ji J., Chen L. Association of lipid-lowering drugs with COVID-19 outcomes from a Mendelian randomization study. Elife. 2021;10:e73873. doi: 10.7554/eLife.73873.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.73873</ArticleId><ArticleId IdType="pmc">PMC8709572</ArticleId><ArticleId IdType="pubmed">34866576</ArticleId></ArticleIdList></Reference><Reference><Citation>Mercep I., Strikic D., Sliskovic A.M., Reiner Z. New Therapeutic Approaches in Treatment of Dyslipidaemia–A Narrative Review. Pharmaceuticals. 2022;15:839. doi: 10.3390/ph15070839.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ph15070839</ArticleId><ArticleId IdType="pmc">PMC9324773</ArticleId><ArticleId IdType="pubmed">35890138</ArticleId></ArticleIdList></Reference><Reference><Citation>Nissen S.E., Lincoff A.M., Brennan D., Ray K.K., Mason D., Kastelein J.J.P., Thompson P.D., Libby P., Cho L., Plutzky J., et al. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients. New Engl. J. Med. 2023;388:1353–1364. doi: 10.1056/NEJMoa2215024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2215024</ArticleId><ArticleId IdType="pubmed">36876740</ArticleId></ArticleIdList></Reference><Reference><Citation>Bays H.E., Bloedon L.T., Lin G., Powell H.A., Louie M.J., Nicholls S.J., Lincoff A.M., Nissen S.E. Safety of bempedoic acid in patients at high cardiovascular risk and with statin intolerance. J. Clin. Lipidol. 2024;18:e59–e69. doi: 10.1016/j.jacl.2023.10.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacl.2023.10.011</ArticleId><ArticleId IdType="pubmed">37951797</ArticleId></ArticleIdList></Reference><Reference><Citation>Bergantini L., Mainardi A., d’Alessandro M., Cameli P., Bennett D., Bargagli E., Sestini P. Common Molecular Pathways Between Post-COVID19 Syndrome and Lung Fibrosis: A Scoping Review. Front. Pharmacol. 2022;13:748931. doi: 10.3389/fphar.2022.748931.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2022.748931</ArticleId><ArticleId IdType="pmc">PMC8931519</ArticleId><ArticleId IdType="pubmed">35308222</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah M.D., Sumeh A.S., Sheraz M., Kavitha M.S., Venmathi Maran B.A., Rodrigues K.F. A mini-review on the impact of COVID 19 on vital organs. Biomed. Pharmacother. 2021;143:112158. doi: 10.1016/j.biopha.2021.112158.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopha.2021.112158</ArticleId><ArticleId IdType="pmc">PMC8416601</ArticleId><ArticleId IdType="pubmed">34507116</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen X., Hu F., Chai F., Chen X. Effect of statins on pulmonary function in patients with chronic obstructive pulmonary disease: A systematic review and meta-analysis of randomized controlled trials. J. Thorac. Dis. 2023;15:3944–3952. doi: 10.21037/jtd-23-1042.</Citation><ArticleIdList><ArticleId IdType="doi">10.21037/jtd-23-1042</ArticleId><ArticleId IdType="pmc">PMC10407522</ArticleId><ArticleId IdType="pubmed">37559605</ArticleId></ArticleIdList></Reference><Reference><Citation>Podolanczuk A.J., Raghu G., Tsai M.Y., Kawut S.M., Peterson E., Sonti R., Rabinowitz D., Johnson C., Barr R.G., Hinckley Stukovsky K., et al. Cholesterol, lipoproteins and subclinical interstitial lung disease: The MESA study. Thorax. 2017;72:472–474. doi: 10.1136/thoraxjnl-2016-209568.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/thoraxjnl-2016-209568</ArticleId><ArticleId IdType="pmc">PMC5388565</ArticleId><ArticleId IdType="pubmed">28130491</ArticleId></ArticleIdList></Reference><Reference><Citation>Bates S.R., Tao J.Q., Collins H.L., Francone O.L., Rothblat G.H. Pulmonary abnormalities due to ABCA1 deficiency in mice. Am. J. Physiol. Lung Cell Mol. Physiol. 2005;289:L980–L989. doi: 10.1152/ajplung.00234.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajplung.00234.2005</ArticleId><ArticleId IdType="pubmed">16055479</ArticleId></ArticleIdList></Reference><Reference><Citation>Romero F., Shah D., Duong M., Penn R.B., Fessler M.B., Madenspacher J., Stafstrom W., Kavuru M., Lu B., Kallen C.B., et al. A pneumocyte-macrophage paracrine lipid axis drives the lung toward fibrosis. Am. J. Respir. Cell Mol. Biol. 2015;53:74–86. doi: 10.1165/rcmb.2014-0343OC.</Citation><ArticleIdList><ArticleId IdType="doi">10.1165/rcmb.2014-0343OC</ArticleId><ArticleId IdType="pmc">PMC4566113</ArticleId><ArticleId IdType="pubmed">25409201</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y., Zhu X., Wu G., Shen L., Chen B. Effect of lipid-bound apoA-I cysteine mutants on lipopolysaccharide-induced endotoxemia in mice. J. Lipid Res. 2008;49:1640–1645. doi: 10.1194/jlr.M700446-JLR200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1194/jlr.M700446-JLR200</ArticleId><ArticleId IdType="pubmed">18458046</ArticleId></ArticleIdList></Reference><Reference><Citation>Fessler M.B. A New Frontier in Immunometabolism. Cholesterol in Lung Health and Disease. Ann. Am. Thorac. Soc. 2017;14:S399–S405. doi: 10.1513/AnnalsATS.201702-136AW.</Citation><ArticleIdList><ArticleId IdType="doi">10.1513/AnnalsATS.201702-136AW</ArticleId><ArticleId IdType="pmc">PMC5711269</ArticleId><ArticleId IdType="pubmed">29161079</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao M., Liu Y., Yuan J., Wen Y., Xu G., Zhao J., Cheng L., Li J., Wang X., Wang F., et al. Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19. Nat. Med. 2020;26:842–844. doi: 10.1038/s41591-020-0901-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-0901-9</ArticleId><ArticleId IdType="pubmed">32398875</ArticleId></ArticleIdList></Reference><Reference><Citation>Preuss I., Ludwig M.G., Baumgarten B., Bassilana F., Gessier F., Seuwen K., Sailer A.W. Transcriptional regulation and functional characterization of the oxysterol/EBI2 system in primary human macrophages. Biochem. Biophys. Res. Commun. 2014;446:663–668. doi: 10.1016/j.bbrc.2014.01.069.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2014.01.069</ArticleId><ArticleId IdType="pubmed">24480442</ArticleId></ArticleIdList></Reference><Reference><Citation>Foo C.X., Bartlett S., Chew K.Y., Ngo M.D., Bielefeldt-Ohmann H., Arachchige B.J., Matthews B., Reed S., Wang R., Smith C., et al. GPR183 antagonism reduces macrophage infiltration in influenza and SARS-CoV-2 infection. Eur. Respir. J. 2023;61:2201306. doi: 10.1183/13993003.01306-2022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.01306-2022</ArticleId><ArticleId IdType="pmc">PMC9686317</ArticleId><ArticleId IdType="pubmed">36396144</ArticleId></ArticleIdList></Reference><Reference><Citation>Madenspacher J.H., Morrell E.D., Gowdy K.M., McDonald J.G., Thompson B.M., Muse G., Martinez J., Thomas S., Mikacenic C., Nick J.A., et al. Cholesterol 25-hydroxylase promotes efferocytosis and resolution of lung inflammation. JCI Insight. 2020;5 doi: 10.1172/jci.insight.137189.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.137189</ArticleId><ArticleId IdType="pmc">PMC7308063</ArticleId><ArticleId IdType="pubmed">32343675</ArticleId></ArticleIdList></Reference><Reference><Citation>Edwards P.A., Kennedy M.A., Mak P.A. LXRs; oxysterol-activated nuclear receptors that regulate genes controlling lipid homeostasis. Vasc. Pharmacol. 2002;38:249–256. doi: 10.1016/S1537-1891(02)00175-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1537-1891(02)00175-1</ArticleId><ArticleId IdType="pubmed">12449021</ArticleId></ArticleIdList></Reference><Reference><Citation>Zanotti I., Poti F., Pedrelli M., Favari E., Moleri E., Franceschini G., Calabresi L., Bernini F. The LXR agonist T0901317 promotes the reverse cholesterol transport from macrophages by increasing plasma efflux potential. J. Lipid Res. 2008;49:954–960. doi: 10.1194/jlr.M700254-JLR200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1194/jlr.M700254-JLR200</ArticleId><ArticleId IdType="pubmed">18252848</ArticleId></ArticleIdList></Reference><Reference><Citation>Kloudova A., Guengerich F.P., Soucek P. The Role of Oxysterols in Human Cancer. Trends Endocrinol. Metab. 2017;28:485–496. doi: 10.1016/j.tem.2017.03.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tem.2017.03.002</ArticleId><ArticleId IdType="pmc">PMC5474130</ArticleId><ArticleId IdType="pubmed">28410994</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohashi H., Wang F., Stappenbeck F., Tsuchimoto K., Kobayashi C., Saso W., Kataoka M., Yamasaki M., Kuramochi K., Muramatsu M., et al. Identification of Anti-Severe Acute Respiratory Syndrome-Related Coronavirus 2 (SARS-CoV-2) Oxysterol Derivatives In Vitro. Int. J. Mol. Sci. 2021;22:3163. doi: 10.3390/ijms22063163.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22063163</ArticleId><ArticleId IdType="pmc">PMC8003796</ArticleId><ArticleId IdType="pubmed">33808940</ArticleId></ArticleIdList></Reference><Reference><Citation>Agudelo C.W., Samaha G., Garcia-Arcos I. Alveolar lipids in pulmonary disease. A review. Lipids Health Dis. 2020;19:122. doi: 10.1186/s12944-020-01278-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12944-020-01278-8</ArticleId><ArticleId IdType="pmc">PMC7268969</ArticleId><ArticleId IdType="pubmed">32493486</ArticleId></ArticleIdList></Reference><Reference><Citation>Calfee C.S., Delucchi K.L., Sinha P., Matthay M.A., Hackett J., Shankar-Hari M., McDowell C., Laffey J.G., O’Kane C.M., McAuley, D.F., on behalf of the Irish Critical Care Trials Group Acute respiratory distress syndrome subphenotypes and differential response to simvastatin: Secondary analysis of a randomised controlled trial. Lancet Respir. Med. 2018;6:691–698. doi: 10.1016/S2213-2600(18)30177-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(18)30177-2</ArticleId><ArticleId IdType="pmc">PMC6201750</ArticleId><ArticleId IdType="pubmed">30078618</ArticleId></ArticleIdList></Reference><Reference><Citation>Zapatero-Belinchon F.J., Moeller R., Lasswitz L., van Ham M., Becker M., Brogden G., Rosendal E., Bi W., Carriqui-Madronal B., Islam K., et al. Fluvastatin mitigates SARS-CoV-2 infection in human lung cells. iScience. 2021;24:103469. doi: 10.1016/j.isci.2021.103469.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.isci.2021.103469</ArticleId><ArticleId IdType="pmc">PMC8599137</ArticleId><ArticleId IdType="pubmed">34812415</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashimoto R., Takahashi J., Shirakura K., Funatsu R., Kosugi K., Deguchi S., Yamamoto M., Tsunoda Y., Morita M., Muraoka K., et al. SARS-CoV-2 disrupts respiratory vascular barriers by suppressing Claudin-5 expression. Sci. Adv. 2022;8:eabo6783. doi: 10.1126/sciadv.abo6783.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciadv.abo6783</ArticleId><ArticleId IdType="pmc">PMC9491726</ArticleId><ArticleId IdType="pubmed">36129989</ArticleId></ArticleIdList></Reference><Reference><Citation>Liebhaber M.I., Wright R.S., Gelberg H.J., Dyer Z., Kupperman J.L. Polymyalgia, hypersensitivity pneumonitis and other reactions in patients receiving HMG-CoA reductase inhibitors: A report of ten cases. Chest. 1999;115:886–889. doi: 10.1378/chest.115.3.886.</Citation><ArticleIdList><ArticleId IdType="doi">10.1378/chest.115.3.886</ArticleId><ArticleId IdType="pubmed">10084510</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>